

(19) **DANMARK**

(10) **DK/EP 1088098 T4**



(12) **Oversættelse af ændret  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 31/35 (2006.01)**                      **A 61 K 31/426 (2006.01)**                      **A 61 K 31/4523 (2006.01)**  
**A 61 K 31/47 (2006.01)**                      **A 61 P 31/18 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-09-14**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om opretholdelse af patentet i ændret form: **2015-07-01**
- (86) Europæisk ansøgning nr.: **99931861.1**
- (86) Europæisk indleveringsdag: **1999-06-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2001-04-04**
- (86) International ansøgning nr.: **US1999014119**
- (87) Internationalt publikationsnr.: **WO1999067417**
- (30) Prioritet: **1998-06-23 US 90393 P**
- (84) Designerede stater: **AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE**
- (73) Patenthaver: **THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852, USA**  
**THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, 352 Henry Administration Building, 506 South Wright Street, Urbana, IL 61801, USA**
- (72) Opfinder: **GULNIK, Sergei, V., 8004 Meadowview Drive, Frederick, MD 21702, USA**  
**MITSUYA, Hiroaki, 4601 North Park Avenue, Apart. 1010, Chevy Chase, MD 20815, USA**  
**ERICKSON, John, W., 5406 Jefferson Boulevard, Frederick, MD 21703, USA**  
**GOSH, Arun K., 1407 Clinton Place, , River Forest, IL60305, USA**
- (74) Fuldmægtig i Danmark: **HØIBERG A/S, Store Kongensgade 59A, 1264 København K, Danmark**
- (54) Benævnelse: **Fitnessassay og fremgangsmåder til reducere af HIV-resistens over for terapi**
- (56) Fremdragne publikationer:  
**WO-A-90/09191**  
**WO-A-94/14793**  
**WO-A-95/06030**  
**WO-A-96/28463**  
**WO-A-97/19055**  
**GB-A- 2 276 621**  
**US-A- 5 502 060**  
**US-A- 5 703 076**  
**US-A- 5 705 500**  
**US-A- 5 723 490**  
**US-A- 5 728 718**  
**US-A- 5 753 660**

Fortsættes ...

US-A- 5 766 842

KLABE, RONALD M. ET AL.: ""Resistance to HIV Protease Inhibitors: A Comparison of enzyme Inhibition and antiviral Potency"" BIOCHEMISTRY, vol. 37, no. 24, 1998, pages 8735-8742, XP002126126

BORMAN, ANDREW M. ET AL: "Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug" J. GEN. VIROL. , vol. 77, no. 3, 1996, pages 419-426, XP002126127

MARTINEZ-PICADO, JAVIER ET AL: "Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1" J. VIROL., vol. 73, no. 5, 1999, pages 3744-3752, XP002126128

WO-A1-97/01349

A. K. GHOSH ET AL.: 'Bioorganic & Medicinal Chemistry Letters', vol. 8, 17 March 1998, ELSEVIER SCIENCE LTD. pages 687 - 690

B. G. GAZZARD ET AL.: 'British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals' THE LANCET vol. 349, 12 April 1997, pages 1086 - 1092

S. DE MEYER ET AL.: 'Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials' AIDS RESEARCH AND HUMAN RETROVIRUSES vol. 24, no. 3, 2008, pages 379 - 388

Y. KOH ET AL.: 'Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1' JOURNAL OF VIROLOGY vol. 85, no. 19, October 2011, pages 10079 - 10089

Mascolini, 10th International Congress on Drug Therapy in HIV Infection, Internet citation,

[http://www.natap.org/2010/interHIV/InterHIV\\_09.htm](http://www.natap.org/2010/interHIV/InterHIV_09.htm) (Nov. 2010) XP55167878

G. MOYLE ET AL.: 'The role of combinations of HIV protease inhibitors in the management of persons with HIV infection' EXPERT OPINION ON INVESTIGATIONAL DRUGS vol. 7, no. 3, March 1998, pages 413 - 426

PRNewswire press release, Internet Citation, <http://www.prnewswire.com/news-releases/double-protease-inhibitor-regimens-containing-vertex-hiv-protease-inhibitor-amprenavir-show-promise-76539677.html> (02 February 1998) XP55167875

J. C. ADKINS ET AL.: 'Adis New Drug Profile' DRUGS vol. 55, no. 6, June 1998, pages 837 - 842

Schafer, HIV InSite Internet Citation <http://hivinsite.ucsf.edu/InSite?page=kb-02-02-03> (June 2002)

XP055167884

## DESCRIPTION

### TECHNICAL FIELD OF THE INVENTION

**[0001]** The present invention relates to the use of a compound in the preparation of a medicament for treating an HIV-infected mammal, in combination with an antiviral agent selected from the group consisting of ritonavir, indinavir, and saquinavir.

### BACKGROUND OF THE INVENTION

**[0002]** The development of drug resistance is one of the most perplexing challenges in the field of medicine. One of the most common causes of drug failure in the treatment of diseases involving replicating biological entities, for example, cancer and infectious diseases, is the emergence of drug resistance. One of the most dramatic and tragic examples of drug resistance can be found in connection with the antiviral therapy of acquired immune deficiency syndrome (AIDS).

**[0003]** AIDS is a fatal disease, reported cases of which have increased dramatically within the past several years. Estimates of reported cases in the very near future also continue to rise dramatically.

**[0004]** The AIDS virus was first identified in 1983. It has been known by several names and acronyms. It is the third known T-lymphocyte virus (HTLV-III), and it has the capacity to replicate within cells of the immune system, causing profound cell destruction. The AIDS virus is a retrovirus, a virus that uses reverse transcriptase during replication. This particular retrovirus is also known as lymphadenopathy-associated virus (LAV), AIDS-related virus (ARV) and, most recently, as human immunodeficiency virus (HIV). Two distinct families of HIV have been described to date, namely HIV-1 and HIV-2. The acronym HIV will be used herein to refer to HIV viruses generically.

**[0005]** Specifically, HIV is known to exert a profound cytopathic effect on the CD4+ helper/inducer T-cells, thereby severely compromising the immune system. HIV infection also results in neurological deterioration and, ultimately, in the death of the infected individual.

**[0006]** The field of viral chemotherapeutics has developed in response to the need for agents effective against retroviruses, in particular HIV. For example anti-retroviral agents, such as 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyinosine (ddI) are known to inhibit reverse transcriptase. There also exist antiviral agents that inhibit transactivator protein. Nucleoside analogs, such as AZT, are currently available for antiviral therapy. Although very useful, the utility of AZT and related compounds is limited by toxicity and insufficient therapeutic indices for fully adequate therapy.

**[0007]** Retroviral protease inhibitors also have been identified as a class of anti-retroviral agents. Retroviral proteases processes polyprotein precursors into viral structural proteins and replicative enzymes. This processing is essential for the assembly and maturation of fully infectious virions. Accordingly, the design of protease inhibitors remains an important therapeutic goal in the treatment of AIDS.

**[0008]** The use of HIV protease inhibitors, in combination with agents that have different antiretroviral mechanisms (e.g., AZT, ddI and ddT), also has been described. For example, synergism against HIV-1 has been observed between certain C<sub>2</sub> symmetric HIV inhibitors and AZT (Kageyama et al., *Antimicrob. Agents Chemother.*, 36, 926-933 (1992)).

**[0009]** Numerous classes of potent peptidic inhibitors of protease have been designed using the natural cleavage site of the precursor polyproteins as a starting point. These inhibitors typically are peptide substrate analogs in which the scissile P<sub>1</sub>-P<sub>1</sub>' amide bond has been replaced by a non-hydrolyzable isostere with tetrahedral geometry (Moore et al, *Perspect. Drug Dis. Design*, 1, 85 (1993); Tomasselli et al., *Int. J. Chem. Biotechnology*, 6 (1991); Huff, *J. Med. Chem.*, 34, 2305 (1991); Norbeck et al., *Ann. Reports Med. Chem.*, 26, 141 (1991); and Meek, *J. Enzyme Inhibition*, 6, 65 (1992)). Although these inhibitors are effective in preventing the retroviral protease from functioning, the inhibitors suffer from some distinct disadvantages. Generally, peptidomimetics often make poor drugs, due to their potential adverse pharmacological properties, i.e., poor oral absorption, poor stability and rapid metabolism (Plattner et al, *Drug Discovery Technologies*, Clark et al., eds., Ellis Horwood, Chichester, England (1990)).

**[0010]** The design of the HIV-1 protease inhibitors based on the transition state mimetic concept has led to the generation of a variety of peptide analogs highly active against viral replication *in vitro* (Erickson et al, *Science*, 249, 527-533 (1990); Kramer et al., *Science*, 231, 1580-1584 (1986); McQuade et al., *Science*, 247, 454-456 (1990); Meek et al., *Nature (London)*, 343, 90-92 (1990); and Roberts et al., *Science*, 248, 358-361 (1990)). These active agents contain a non-hydrolyzable, dipeptidic isostere, such as hydroxyethylene (McQuade et al., *supra*; Meek et al., *Nature (London)*, 343, 90-92 (1990); and Vacca et al., *J. Med. Chem.*, 34, 1225-1228 (1991)) or hydroxyethylamine (Ghosh et al., *Bioorg. Med. Chem. Lett.*, 8, 687-690 (1998); Ghosh et al., *J. Med. Chem.*, 36, 292-295 (1993); Rich et al., *J. Med. Chem.*, 33, 1285-1288 (1990); and Roberts et al., *Science*, 248, 358-361 (1990)) as an active moiety that mimics the putative transition state of the aspartic protease-catalyzed reaction.

**[0011]** Two-fold (C<sub>2</sub>) symmetric inhibitors of HIV protease represent another class of potent HIV protease inhibitors, which were created by Erickson et al., on the basis of the three-dimensional symmetry of the enzyme active site (Erickson et al. (1990), *supra*). Typically, however, the usefulness of currently available HIV protease inhibitors in the treatment of AIDS has been limited by relatively short plasma half-life, poor oral bioavailability, and the technical difficulty of scale-up synthesis (Meek et al. (1992), *supra*).

**[0012]** In a continuing effort to address the problem of short plasma half-life and poor bioavailability, new HIV protease inhibitors have been identified. For example, HIV protease inhibitors incorporating the 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isostere are described in Ghosh et al., *Bioorg. Med. Chem. Lett.*, 8, 687-690 (1998) and U.S. Patent Nos. 5,728,718 (Randad et al.). HIV protease inhibitors, which incorporate the hydroxyethylamine isostere, are described in U.S. Patent Nos. 5,502,060 (Thompson et al.), 5,703,076 (Talley et al.), and 5,475,027 (Talley et al.).

**[0013]** Recent studies, however, have revealed the emergence of mutant strains of HIV, in which the protease is resistant to the C<sub>2</sub> symmetric inhibitors (Otto et al., *PNAS USA*, 90, 7543 (1993); Ho et al., *J. Virology*, 68, 2016-2020 (1994); and Kaplan et al., *PNAS USA*, 91, 5597-5601 (1994)). In one study, the most abundant mutation found in response to a C<sub>2</sub> symmetry based inhibitor was Arg to Gln at position 8 (R8Q), which strongly affects the S<sub>3</sub>/S<sub>3</sub>' subsite of the protease binding domain. In this study, the shortening of the P<sub>3</sub>/P<sub>3</sub>' residues resulted in inhibitors that were equipotent towards both wild-type and R8Q mutant proteases (Majer et al., 13th American Peptide Symposium, Edmonton, Canada (1993)). Inhibitors have been truncated to P<sub>2</sub>/P<sub>2</sub>' without significant loss of activity (Lyle et al., *J. Med.*

Chem., 34, 1230 (1991); and Bone et al., J. Am. Chem. Soc., 113, 9382 (1991)). These results suggest that inhibitors can be truncated and yet maintain the crucial interaction necessary for strong binding. The benefits of such an approach include the elimination of two or more peptide bonds, the reduction of molecular weight, and the diminishment of the potential for recognition by degradative enzymes.

**[0014]** More recently, new mutant strains of HIV have emerged that are resistant to multiple, structurally diverse, experimental and chemotherapeutic retroviral protease inhibitors. Such multidrug-resistant HIV strains are typically found in infected patients, who had undergone treatment with a combination of HIV protease inhibitors or a series of different HIV protease inhibitors. The number of reported cases of patients infected with multidrug-resistant HIV is rising dramatically. Tragically for these patients, the available options for AIDS chemotherapy and/or HIV management is severely limited or is, otherwise, completely nonexistent.


**[0015]** Drug resistance is unfortunately the most common reason for drug failures generally. One of the most dramatic examples of drug failure due to resistance is in HIV therapy. Once HIV resistance is obtained to first-line therapy, the chances of future success are greatly diminished because of the development of multidrug cross resistance. Other diseases involving infectious agents (e.g., viruses, bacteria, protozoa, and prions) or other disease-causing cells (e.g., tumor cells) present similar challenges in that drug resistance is a primary cause of drug failure.

**[0016]** In view of the foregoing problems, there exists a need to determine whether a mutant will be capable of replicating in the presence of a drug. There also exists a need for a method of predicting whether drug resistance is likely to emerge in a disease involving a replicating biological entity. There is also a need for a method of devising a long-term therapeutic regimen that minimize the likelihood that resistance will occur in a disease involving a replicating biological entity. Moreover, there is a need for a method of preventing or inhibiting the development of drug resistance in such diseases.

**[0017]** The present invention provides such methods. These and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.


#### BRIEF SUMMARY OF THE INVENTION

**[0018]** The present invention pertains to the use of a compound of the formula:



or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of said compound, said salt, said prodrug, or said ester thereof, wherein:

A is a group of the formula:



R<sup>1</sup> is H or an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkylalkyl, an aryl, an aralkyl, a heterocycloalkyl, a heterocycloalkylalkyl, a heteroaryl, or a heteroaralkyl, in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of OR<sup>7</sup>, SR<sup>7</sup>, CN, NO<sub>2</sub>, N<sub>3</sub>, and a halogen, wherein R<sup>7</sup> is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

Y and Z are the same or different and each is selected from the group consisting of CH<sub>2</sub>, O, S, SO, SO<sub>2</sub>, NR<sup>8</sup>, R<sup>8</sup>C(O)N, R<sup>8</sup>C(S)N, R<sup>8</sup>OC(O)N, R<sup>8</sup>OC(S)N, R<sup>8</sup>SC(O)N, R<sup>8</sup>R<sup>9</sup>NC(O)N, and R<sup>8</sup>R<sup>9</sup>NC(S)N, wherein R<sup>8</sup> and R<sup>9</sup> are the same or different and each is selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

n is an integer from 1 to 5;

X is a covalent bond, CHR<sup>10</sup>, CHR<sup>10</sup>CH<sub>2</sub>, CH<sub>2</sub>CHR<sup>10</sup>, O, NR<sup>10</sup>, or S, wherein R<sup>10</sup> is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

Q is C(O), C(S), or SO<sub>2</sub>;

R<sup>2</sup> is H, a C<sub>1</sub>-C<sub>6</sub> alkyl, a C<sub>2</sub>-C<sub>6</sub> alkenyl, or a C<sub>2</sub>-C<sub>6</sub> alkynyl;

m is an integer from 0 to 6;

R<sup>3</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of alkyl, (CH<sub>2</sub>)<sub>p</sub>R<sup>11</sup>, OR<sup>12</sup>, SR<sup>12</sup>, CN, N<sub>3</sub>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, C(O)R<sup>12</sup>, C(S)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, C(O)SR<sup>12</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, C(S)NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>C(S)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>13</sup>, NR<sup>12</sup>C(O)SR<sup>13</sup>, and a halogen, wherein:

p is an integer from 0 to 5;

R<sup>11</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH, OCH<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub> SH, and CN; and

R<sup>12</sup> and R<sup>13</sup> are the same or different and each is selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

$R^4$  is OH, =O (keto) or  $NH_2$ , wherein, when  $R^4$  is OH, it is optionally in the form of a pharmaceutically acceptable ester or prodrug, and when  $R^4$  is  $NH_2$ , it is optionally an amide, a hydroxylamino, a carbamate, a urea, an alkylamino, a dialkylamino, a protic salt thereof, or a tetraalkylammonium salt thereof;

$R^5$  is H, a C<sub>1</sub>-C<sub>6</sub> alkyl radical, a C<sub>2</sub>-C<sub>6</sub> alkenyl radical, or  $(CH_2)_qR^{14}$  wherein q is an integer from 0 to 5, and  $R^{14}$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH, OCH<sub>3</sub>,  $NH_2$ ,  $NO_2$ , SH, and CN;

W is C(O), C(S), or  $SO_2$ ; and

$R^6$  is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen,  $OR^{15}$ ,  $SR^{15}$ ,  $S(O)R^{15}$ ,  $SO_2R^{15}$ ,  $SO_2NR^{15}R^{16}$ ,  $SO_2N(OH)R^{15}$ , CN,  $CR^{15}=NR^{16}$ ,  $CR^{15}=N(OR^{16})$ ,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $N(OH)R^{15}$ ,  $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $C(O)N(OH)R^{15}$ ,  $C(S)N(OH)R^{15}$ ,  $NR^{15}C(O)R^{16}$ ,  $NR^{15}C(S)R^{16}$ ,  $N(OH)CCO)R^{15}$ ,  $N(OH)C(S)R^{15}$ ,  $NR^{15}CO_2R^{16}$ ,  $N(OH)CO_2R^{15}$ ,  $NRC^{15}(O)SR^{16}$ ,  $NR^{15}C(O)NR^{16}R^{17}$ ,  $NR^{15}C(S)NR^{16}R^{17}$ ,  $N(OH)C(O)NR^{15}R^{16}$ ,  $N(OH)C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)N(OH)R^{16}$ ,  $NR^{15}C(S)N(OH)R^{16}$ ,  $NR^{15}SO_2R^{16}$ ,  $NHSO_2NR^{15}R^{16}$ ,  $NR^{15}SO_2NHR^{16}$ ,  $P(O)(OR^{15})(OR^{16})$ , an alkyl, an alkoxy, an alkylthio, an alkylamino, a cycloalkyl, a cycloalkylalkyl, a heterocycloalkyl, a heterocycloalkylalkyl, an aryl, an aryloxy, an arylamino, an arylthio, an aralkyl, an aryloxyalkyl, an arylaminoalkyl, an aralkoxy, an (aryloxy)alkoxy, an (arylamino)alkoxy, an (arylthio)alkoxy, an aralkylamino, an (aryloxy)alkylamino, an (arylamino)alkylamino, an (arylthio)alkylthio, an (aryloxy)alkylthio, an (arylamino)alkylthio, an (arylthio)alkylthio, a heteroaryl, a heteroaryloxy, a heteroarylamino, a heteroarylthio, a heteroaralkyl, a heteroaralkoxy, a heteroaralkylamino, and a heteroaralkylthio,

wherein  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  are H, an unsubstituted alkyl, or an unsubstituted alkenyl,

wherein, when at least one hydrogen atom of  $R^6$  is substituted with a substituent other than a halogen,  $OR^{15}$ ,  $SR^{15}$ , CN,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)R^{16}$ ,  $NR^{15}C(S)R^{16}$ ,  $NR^{15}CO_2R^{16}$ ,  $NR^{15}C(O)SR^{16}$ ,  $NR^{15}C(O)NR^{16}R^{17}$ , or  $NR^{15}C(S)NR^{16}R^{17}$ , at least one hydrogen atom on said substituent is optionally substituted with a halogen,  $OR^{15}$ ,  $SR^{15}$ , CN,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)R^{16}$ ,  $NR^{15}C(S)R^{16}$ ,  $NR^{15}CO_2R^{16}$ ,  $NR^{15}C(O)SR^{16}$ ,  $NR^{15}CCO)NR^{16}R^{17}$ , or  $NR^{15}C(S)NR^{16}R^{17}$ ; in a resistance-inhibiting effective amount in the preparation of a medicament for treating an HIV-infected mammal, in combination with an antiviral agent selected from the group consisting of ritonavir, indinavir, and saquinavir in a pharmaceutically acceptable carrier.

## BRIEF DESCRIPTION OF THE DRAWINGS

### [0019]

Fig. 1 illustrates the synthesis of a particular sulfonamide isostere core of a compound.

Figure 2 illustrates the synthesis of a bis-tetrahydrofuran ligand and the optical resolution thereof.

Fig. 3A illustrates the synthesis of a compound via coupling of a bis-tetrahydrofuran ligand to a sulfonamide isostere.

Fig. 3B illustrates the synthesis of a compound via coupling of a bis-tetrahydrofuran ligand to a sulfonamide isostere.

Figure 4 illustrates generally the present method of synthesizing a compound.

Figures 5A-5D illustrate the structures of particular compounds that were tested against various drug resistant HIV mutants.

## DESCRIPTION OF THE PREFERRED EMBODIMENT

[0020] The "vitality" of a biochemical target of a mutant replicating biological entity relative to that of its predecessor's biochemical target can be used to predict the biological fitness of the mutant under the selection pressure of an inhibitor of the biochemical target. The "vitality" of a biochemical target of a mutant replicating biological entity relative to the "vitality" of its predecessor's biochemical target is defined herein as the "biochemical fitness."

[0021] "Vitality" as utilized herein describes the ability of a particular biomolecular "target" (i.e., a biochemical species intended to be inhibited by a particular inhibitor) to perform its biochemical function in the presence of the inhibitor. Biochemical vitality is a function of at least two variables: the ability of a particular inhibitor to inhibit a biochemical target of the replicating biological entity in question, and the ability of the cell's biochemical target to inherently perform its biochemical function (irrespective of an inhibitor). Biochemical vitality also can include other factors that effect the ability of a biochemical target to perform its biochemical function in the presence of the inhibitor.

[0022] The biochemical target in question can include, for example, a biochemical species with one or more known or unknown biological functions. The biochemical target can be, for example, a biochemical species having one or more specific biochemical function, or it can be a biochemical species that effects or influences a biochemical function directly or indirectly. Suitable biochemical targets include, for example, enzymes, proteins, oligomers, receptors, and the like. Suitable enzymes include, for example, reverse transcriptases, proteases (e.g., retroviral proteases, plasmepsins, and the like), methylases, oxidases, esterases, acyl transferases, and the like. Suitable enzymes also include, for example, viral and non-viral helicases, topoisomerases, DNA gyrases, DNA and RNA polymerases, parasite-encoded proteases, and the like.

[0023] Suitable proteins include, for example, proteins that incorporate a conformational change as a major functional requirement, and the like. Examples of such proteins include HIV gp41 and other fusogenic viral proteins and peptides, topoisomerases, and all DNA enzymes, and the like.

**[0024]** Suitable oligomers include, for example, oligomers that require oligomerization in order to perform their biochemical function. Examples of such oligomers include HIV protease, retroviral fusion proteins, peptides, HIV gp 41, viral and non-viral membrane fusion proteins, tumor suppressor proteins (e.g., p53, and the like) prions, ribosomes, and the like.

**[0025]** The ability of a particular inhibitor to inhibit a biochemical target of a particular replicating biological entity can be determined by any suitable method and/or can be obtained from any suitable source. The ability of a particular inhibitor to inhibit a biochemical function of a replicating biological entity can be determined, for example, on the basis of a measurable property, or a measurable relationship of properties, that correlate with the ability of the inhibitor to inhibit the target. Suitable methods for determining the ability of the inhibitor to inhibit the target include, for example, assays, and the like. In some instances, the ability of the inhibitor to inhibit the target can be obtained from one or more suitable sources, for example, assay data from a database, a textbook, or the literature.

**[0026]** When the biochemical target is a protein, the ability of an inhibitor to inhibit the protein can be determined, for example, by obtaining the equilibrium dissociation constant ( $K_d$ ) of drug binding to the target where drug binding interferes with the function of the protein.

**[0027]** When the biochemical target is an enzyme, the ability of an inhibitor to inhibit the enzyme can be determined, for example, by obtaining the inhibition constant ( $K_{inh}$ ), or the like. The inhibition constant can be in terms of drug inhibition constant for the effect of the drug on substrate catalysis (e.g.,  $K_I$ ) or dissociation constant for drug binding (e.g.,  $K_d$ ) where drug binding correlates with inhibition of enzyme function.

**[0028]** When the biochemical target is an oligomer, the ability of an inhibitor to inhibit the oligomer can be determined, for example, by obtaining the equilibrium dissociation constant ( $K_d$ ) for drug binding where drug binding interferes with oligomerization of the target.

**[0029]** Where the biochemical target is a protein that requires a conformational change for its function, use ability of an inhibitor to inhibit the conformational change can be determined, for example, by obtaining the equilibrium dissociation constant ( $K_d$ ) for drug binding where drug binding interferes with the conformational change of the target.

**[0030]** When the biochemical target is a protein that is required to bind to a ligand, macromolecule, or macromolecular complex to perform its biochemical function, the ability of an inhibitor to inhibit the protein function can be determined by obtaining the equilibrium dissociation constant ( $K_d$ ) for drug binding where drug binding interferes with ligand binding, macromolecule binding, or macromolecular complex binding.

**[0031]** When the biochemical target is a nucleic acid binding protein, the ability of an inhibitor to inhibit the nucleic acid binding protein's function can be determined by obtaining the equilibrium dissociation constant ( $K_d$ ) for drug binding where drug binding interferes with nucleic acid binding.

**[0032]** Vitality also is a function of the biochemical target's ability to inherently perform its biochemical function (irrespective of an inhibitor). The biochemical target's ability to inherently perform its biochemical function can be determined by any suitable method and/or can be obtained from any suitable source. The biochemical target's ability to inherently perform its biochemical function can be determined, for example, on the basis of a measurable property, or measurable relationship of properties, that correlates with the ability of the biochemical target's ability to inherently perform its biochemical function. Suitable methods for determining the biochemical target's ability to inherently perform its biochemical function include, for example, biochemical assays, and the like. In some instances, the ability of a cell's biochemical target to inherently perform its biochemical function can be obtained from one or more suitable sources, for example, assay data from a database, a textbook, or the literature.

**[0033]** When the biochemical target is an enzyme, the ability of the enzyme to inherently perform its biochemical function can be determined, for example, by determining the catalytic efficiency of the enzyme. For example, the catalytic efficiency for enzymes that exhibit Michaelis-Menten kinetics can be determined by obtaining the  $k_{cat}/K_M$  ratio, or by a similar method, wherein  $k_{cat}$  is the catalytic rate and  $K_M$  is the Michaelis constant.

**[0034]** When the biochemical target is a protein, the ability of the protein to inherently perform its biochemical function can be determined, for example, by obtaining the equilibrium constant ( $K_{eq}$ ) for the biochemical function of the protein, or the like.

**[0035]** When the biochemical target is an oligomer, the ability of an inhibitor to perform its biological function can be determined, for example, by obtaining the equilibrium constant ( $K_{eq}$ ) that is associated with oligomerization.

**[0036]** Where the biochemical target is a protein that requires a conformational change for its function, the ability of the target to perform its function can be determined, for example, by obtaining the equilibrium constant ( $K_{eq}$ ) associated with conformational change.

**[0037]** When the biochemical target is a protein that is required to bind to a ligand to perform its function, the ability of the target to perform its function can be determined, for example, by obtaining the equilibrium dissociation constant ( $K_d$ ) for ligand binding.

**[0038]** When the biochemical target is a nucleic acid binding protein, the ability of an inhibitor to perform its function can be determined by obtaining the equilibrium dissociation constant ( $K_d$ ) for nucleic acid binding.

**[0039]** It will be appreciated that vitality also can be a function of other factors that effect the ability of a biochemical target to perform its biochemical function in the presence of the inhibitor. If the biochemical target is a dimeric species, for example, other factors that influence biochemical vitality might include the ability of the species to dimerize in the presence and/or in the absence of the inhibitor. If, by way of example, a mutation causes the dimerization rate to become a factor in the biochemical function of the biochemical target of the mutant relative to its predecessor's, then dimerization rate can be included in the vitality determination.

**[0040]** The biochemical vitalities of a mutant replicating biological entity and its predecessor, when compared, describes the biochemical fitness of the target of the mutant cell. It has been found that the biochemical fitness relates to the biological fitness of the mutant in the presence of the inhibitor. When the value for the biochemical vitality of the target of the mutant exceeds the value for the biochemical vitality of the target of a predecessor of the mutant, the target of the mutant has greater biochemical fitness in the presence of the inhibitor. In such cases, the mutant replicating biological entity is favored over the predecessor and resistance to the inhibitor that is used to treat the predecessor is likely to develop.

**[0041]** Biochemical vitality can be determined in many different ways that suitably relate the various factors relating to the biochemical vitality of the target. For example, a mathematical function may be used to relate the various factors. By way of illustration, when the biochemical target is an enzyme, the vitality can be

determined as a function of  $K_{inh}$  (e.g.,  $K_i$  or  $K_d$ ) and enzymatic or catalytic efficiency (e.g.,  $K_{cat}/K_M$ ). Vitality can be determined as the product of  $K_{inh}$  and enzymatic efficiency, for example,  $(K_{inh}) \times (\text{catalytic efficiency})$ , or  $(K_i) \times (\text{catalytic efficiency})$  or  $(K_d) \times (\text{catalytic efficiency})$ . Alternatively, vitality can be determined, for example, as the log of the product of  $K_{inh}$  and enzymatic efficiency, for example,  $\log [(K_{inh}) \times (\text{catalytic efficiency})]$ , or  $\log [(K_i) \times (\text{catalytic efficiency})]$  or  $\log [(K_d) \times (\text{catalytic efficiency})]$ . Similarly, for enzymes that exhibit Michaelis-Menten kinetics, vitality can be determined as a function of  $K_{inh}$  (e.g.,  $K_i$  or  $K_d$ ) and the  $k_{cat}/K_M$  ratio. For example, vitality can be determined as the product of  $K_{inh}$  and  $k_{cat}/K_M$  e.g.,  $(K_{inh}) \times (k_{cat}/K_M)$ , wherein  $K_{inh}$  is  $K_i$  or  $K_d$ . Alternatively, vitality can be determined, for example, as the log of the product of  $K_{inh}$  and  $k_{cat}/K_M$  e.g.,  $\log [(K_{inh}) \times (k_{cat}/K_M)]$ , wherein  $K_{inh}$  is  $K_i$  or  $K_d$ . In a preferred embodiment, the biochemical target is an enzyme and the vitality is  $(K_i) \times (k_{cat}/K_M)$ , or  $\log [(K_i) \times (k_{cat}/K_M)]$ .

**[0042]** "Fitness," unless otherwise indicated, means biochemical fitness. "Biochemical fitness" as utilized herein is a value that represents the vitality of a biochemical target of a mutant replicating biological entity relative to the vitality the biochemical target of its predecessor. Biochemical fitness is determined by comparing the vitality of a biochemical target of a mutant replicating biological entity relative to that of its predecessor. Any suitable comparison of the vitality of a biochemical target of a mutant replicating biological entity relative to that of its predecessor can be used in the determination of fitness. For example, biochemical fitness can be determined as the difference between the biochemical vitality of a biochemical target of a predecessor (biochemical vitality<sub>pred</sub>) and the biochemical vitality of the biochemical target of a particular mutant replicating biological entity that can evolve from the predecessor (biochemical vitality<sub>mut</sub>), e.g., (biochemical vitality<sub>mut</sub>) - (biochemical vitality<sub>pred</sub>). If biochemical fitness is determined on the basis of this difference, then a positive value indicates that the mutant has a higher fitness relative to its predecessor in the presence of the inhibitor, whereas a negative value indicates that the mutant is less fit relative to its predecessor. A value of zero indicates that the fitness of the mutant and the predecessor are equal. A higher positive value indicates a greater chance that resistance to the inhibitor will emerge, whereas a higher negative value indicates a lower chance that resistance to the inhibitor will emerge.

**[0043]** Alternatively, and preferably, fitness can be determined as the quotient of two biochemical vitalities, for example, as the quotient of a biochemical target of a particular mutant replicating biological entity and the biochemical vitality of the biochemical target of a predecessor, e.g.,

$$\text{fitness} = \frac{\text{vitality}_{\text{mut}}}{\text{vitality}_{\text{pred}}}$$

If fitness is determined on the basis of this quotient, then a value greater than one indicates that the mutant has a higher fitness relative to its predecessor, in the presence of the inhibitor. A value of one indicates that the fitness of the mutant and the predecessor are equal. A value less than one indicates that the mutant is less fit relative to its predecessor. A higher value indicates a greater chance that resistance to the inhibitor/drug will emerge, whereas a lower value indicates a lower chance that resistance to the inhibitor/drug will emerge. A value less than one indicates that the mutant will not emerge in the presence of the inhibitor/drug.

**[0044]** Alternatively, fitness can be determined as the log of the quotient of two biochemical vitalities, for example, as the log of the quotient of a biochemical target of a particular mutant replicating biological entity and the biochemical vitality of the biochemical target of a predecessor, e.g.,

$$\text{fitness} = \log \left[ \frac{\text{vitality}_{\text{mut}}}{\text{vitality}_{\text{pred}}} \right]$$

If fitness is determined on the basis of this log, then a value greater than zero indicates that the mutant has a higher fitness relative to its predecessor, in the presence of the inhibitor. A negative value indicates that the mutant is less fit relative to its predecessor. A value of zero indicates that the fitness of the mutant and the predecessor are equal. A higher positive value indicates a greater chance that resistance to the inhibitor/drug will emerge, whereas a lower positive value indicates a lower chance that resistance to the inhibitor/drug will emerge. A negative value indicates that the mutant will not emerge in the presence of the inhibitor/drug.

**[0045]** Fitness can be determined in the presence of any suitable compound that inhibits a biochemical target from performing its biological function. The inhibitor, for example, can be a compound that inhibits an enzyme. Suitable enzyme inhibitors include, for example, protease inhibitors, reverse transcriptase inhibitors, DNA polymerase inhibitors, methylase inhibitors, oxidase inhibitors, esterase inhibitors, acyl transferase inhibitors, and the like.

**[0046]** Suitable protease inhibitors include, for example, viral protease inhibitors, plasmepsin inhibitors, and cathepsin D inhibitors. In a preferred embodiment, the inhibitor is a viral protease inhibitor, more preferably a retroviral protease inhibitor, still more preferably an HIV-1 or an HIV-2 protease inhibitor, and most preferably an HIV-1 protease inhibitor. Exemplary HIV-1 protease inhibitors include, for example, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and HIV-1 protease inhibitors that are undergoing clinical trials, e.g., tipranavir (PNU-140690).

**[0047]** Suitable plasmepsin inhibitors include, for example, inhibitors of plasmepsin I or II, including inhibitors of plasmepsin I or II that have antimalarial activity. Suitable inhibitors of cathepsin D include, for example, cathepsin D inhibitors that inhibit cathepsin D in primary breast cancer tissues, including cathepsin D inhibitors that inhibit cathepsin D in primary breast cancer tissues and would be expected to lower the risk of metastasis and/or shorter relapse-free survival in breast cancer patients. See, e.g., Gulnik et al., J. Mol. Biol., 227, 265-270 (1992).

**[0048]** Suitable reverse transcriptase inhibitors include, for example, retroviral reverse transcriptase inhibitors, e.g., AZT, 3TC, ddI, ddC, D4T, and the like.

**[0049]** Suitable protein inhibitors include, for example, compounds that inhibit a conformational change in a protein, and the like. Suitable oligomerization inhibitors include, for example, T-20 peptide inhibitor of HIV-1 fusion and other compounds that inhibit oligomers from oligomerizing on a cell surface or within a cell membrane.

**[0050]** Fitness in the presence of an inhibitor can be determined for a biological entity that produces or includes a biological target of the inhibitor. The biological entity is preferably a replicating biological entity, for example, a virus, a parasite, or a cell, preferably a disease-causing cell. Disease-causing replicating biological entities include, for example, tumor cells, cancer cells, and infectious organisms (e.g., fungi, protozoa, bacteria, and the like) and prions.

**[0051]** Cancer cells include, for example, cells associated with breast cancer, colon cancer, lung cancer, and the like. Fitness can be determined for a rapidly growing tumor cell.

**[0052]** Fungi include, for example, candida albicans, and the like. Protozoa include, for example, trypanosome species, schistosomiasis species, malarial protozoa, e.g., Plasmodium species. Plasmodium species include, for example, Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax, Plasmodium malariae, and the like. Bacteria include, for example, Helicobacter pylori; Escherichia coli, Salmonella, Streptococcus pyogenes, Staphylococcus aureus, Bacillus anthrax, Mycobacterium tuberculosis, Hemophilus influenza, and the like. Viruses include, for example, retroviruses (e.g., HIV-1 and HIV-2), herpes viruses, cytomegaloviruses, influenza viruses, epstein-barr virus (EBV), Kaposi's sarcoma herpes virus (KSHV), varicella-zoster virus (VZV), human papillomavirus (HPV), ehovirus, picornaviruses, rhinoviruses, poliovirus, coxsackie virus, measles, mumps, human T-cell leukemia virus (HTLV-1), rubella, rotaviruses, yellow fever virus,

ebola virus, and other pathogenic viruses, and the like.

**[0053]** Replicating biological entities also include multicellular organisms, for example, infectious microorganisms, e.g., helminths. Helminths include, for example, hookworms (e.g., *ancylostoma duodenale*) *strongyloides stercoralis*, *fasciola hepatica*, *trichuris trichiura*, *trichinella spiralis*, *taenia solium*, *taenia saginata*, and the like.

**[0054]** It is believed that drug resistance is the evolutionary result of fitness-based selection of mutant cells/microorganisms in the presence of a drug (or any compound that has biological activity). The emergence (or non-emergence) of drug resistance in a disease caused by a disease-causing replicating biological entity can be predicted by determining the fitness of a biochemical target of a mutant in the presence of the drug. Thus, the emergence (or non-emergence) of drug resistance can be predicted on the basis of biochemical fitness. While resistance profiles may, in some instances, reflect fitness, it cannot be assumed that the emergence of drug resistance for a particular mutant can be directly predicted on the basis of its resistance profile alone.

**[0055]** An assay may be provided that can be used to predict the biological fitness of a replicating biological entity in the presence of a particular inhibitor. An assay may be provided for determining the biochemical fitness of a biochemical target of a mutant replicating biological entity relative to its predecessor. In accordance with the assay, a predecessor to the mutant is obtained, the biochemical vitality of the biochemical target of the predecessor in the presence of a compound capable of inhibiting the biochemical target of the predecessor is determined, the biochemical vitality of the biochemical target of the mutant in the presence of the compound is determined, and the biochemical vitality of the biochemical target of the mutant relative to the biochemical vitality of the biochemical target of the predecessor are compared.

**[0056]** The assay can be used with a wide variety of infectious microorganisms, as described above, including, for example, a virus, a fungus, a protozoa, or bacterium, a retrovirus, including HIV-1 or HIV-2, and cancer cells. When the infectious microorganism is a protozoa, it is preferably a malarial parasite, which is more preferably a plasmodium species.

**[0057]** In another embodiment, the predecessor is a cancer cell, which is preferably a rapidly growing tumor cell, for example, a rapidly growing cancer cell found in breast cancer, colon cancer, lung cancer, a tumor cell of a lymphoid origin, a tumor-derived cell with a high metastatic potential, or the like.

**[0058]** The assay can be applied to any suitable biochemical target, preferably a biochemical target whose biochemical vitality can be determined using measurable properties that can be obtained by assay. Desirably, the biochemical target is one that plays an important role in the replication and growth of the entity. By way of example, the biochemical target of the predecessor (and the mutant) can be an enzyme and the compound can be an inhibitor of the enzyme of the predecessor.

**[0059]** The enzyme can be a viral enzyme. Illustrative of viral enzymes are a viral protease enzyme, a viral reverse transcriptase, a viral integrase, a viral polymerase, a viral protein with enzymatic activity, or a retroviral enzyme, including an HIV-1 or an HIV-2 enzyme. Viral protease enzymes, include a retroviral protease, such as an HIV-1 protease or an HIV-2 protease. Viral integrase enzymes include, for example, HIV-1 integrase, HIV-2 integrase, and the like. Viral polymerase can be a retroviral polymerase, including an HIV-1 polymerase or an HIV-2 polymerase. A viral protein with enzymatic activity can be a retroviral protein, such as an HIV-1 protein or an HIV-2 protein.

**[0060]** The enzyme also can be a protozoal enzyme, including a protozoal protease enzyme. The protozoal protease can be a malarial protease. The malarial protease can be a plasmepsin, including plasmepsin I or plasmepsin II. The malarial enzyme can also be a plasmodial enzyme or a protein with enzymatic activity.

**[0061]** The biochemical target of the predecessor is an oligomer and the compound inhibits the oligomerization of the oligomer of the predecessor. In yet another embodiment, the biochemical target of the predecessor is a protein and the compound inhibits a conformational change in the protein of the predecessor.

**[0062]** The biochemical vitality determination can also take into account other factors, preferably measurable factors, that effect the ability of a biochemical target to perform its biochemical function in the presence of the inhibitor. When the biochemical target is an enzyme and the compound is an enzyme inhibitor, the biochemical vitality of the enzyme of the mutant replicating biological entity preferably corresponds to  $K_{inh-mut}$ ,  $k_{cat-mut}$ ,  $K_M-mut$  and the biochemical vitality of the enzyme of the predecessor preferably corresponds to  $K_{inh-pred}$ ,  $k_{cat-pred}$ , and  $K_M-pred$ .  $K_{inh}$  is an inhibition constant of the compound,  $k_{cat}$  is the biochemical catalytic rate, and  $K_M$  is the Michaelis constant. More preferably, the vitality of the enzyme corresponds to  $K_{inh}$ ,  $k_{cat}$  and  $K_M$  and the biochemical vitality of the enzyme of the mutant replicating biological entity is defined by the relationship  $K_{inh-mut} (k_{cat-mut}/K_M-mut)$  (i.e.,  $(K_{inh-mut}) \times (k_{cat-mut}/K_M-mut)$ ) and the biochemical vitality of the enzyme of the predecessor is defined by the relationship  $K_{inh-pred}(k_{cat-pred}/K_M-pred)$ . The variables  $K_{inh-mut}$ ,  $K_{inh-pred}$ ,  $k_{cat-mut}$ ,  $k_{cat-pred}$ ,  $K_M-mut$ , and  $K_M-pred$  can be obtained by any suitable means, and are preferably obtained by measurement (e.g., from an assay). When vitality is determined on the basis of these relationships, biochemical fitness in the presence of a given inhibitor/drug preferably is defined by the equation:

$$\frac{K_{inh-mut} (k_{cat-mut} / K_M-mut)}{K_{inh-pred} (k_{cat-pred} / K_M-pred)}$$

or

$$\log \left[ \frac{K_{inh-mut} (k_{cat-mut} / K_M-mut)}{K_{inh-pred} (k_{cat-pred} / K_M-pred)} \right]$$

$K_{inh}$  can be determined by any suitable means, but typically is determined on the basis of  $K_i$  or  $K_d$ .

**[0063]** A method of administering a therapeutic compound may be provided, which method increases the chances of successful long-term therapy. A method of administering a therapeutic compound may be provided that inhibits a biochemical target of a replicating disease-causing replicating biological entity (disease causing predecessor), including identifying at least one mutant capable of evolving from the disease-causing predecessor. A first biochemical vitality of the biochemical target of the disease-causing predecessor in the presence of a first compound capable of inhibiting the biochemical target of the disease-causing predecessor, and a first biochemical vitality of the biochemical target of the mutant in the presence of the first compound, are determined.

**[0064]** Additional biochemical vitalities of the biochemical target of the disease-causing replicating biological entity in the presence of additional compounds capable of inhibiting the biochemical target of the disease-causing cell, and additional biochemical vitalities of the biochemical target of the mutant in the presence of the additional compounds, are also determined.

**[0065]** Fitnesses in the presence of different inhibitors/drugs can be compared and a therapeutic compound administered on the basis of the comparison. A first biochemical fitness of the biochemical target of the mutant relative to the disease-causing predecessor is determined by comparing the first biochemical vitality of the



biochemical target of the mutant with the first biochemical vitality of the biochemical target of the disease-causing predecessor, and a second biochemical fitness of the biochemical target of the mutant relative to the disease-causing replicating biological entity is determined by comparing the second biochemical vitality of the biochemical target of the mutant with the second biochemical vitality of the biochemical target of the disease-causing replicating biological entity. Additional biochemical fitness determination can be made in the presence of additional compounds. The biochemical fitness values for one or more mutants in the presence of each compound are compared. A therapeutic compound is then administered from among the first and the additional compound(s), which therapeutic compound produces the lowest biochemical fitness values.

**[0066]** In accordance with the method, the replicating disease-causing replicating biological entity is less likely to develop resistance in the presence of the therapeutic compound. The therapeutic compound can be administered from among any particular set of compounds, which can have the same biochemical target or different biochemical targets with respect to each other. The method of administering a compound is, therefore, not limited to comparing fitness in the presence of compounds that act on the same biochemical target.

**[0067]** The disease-causing replicating biological entity is an infectious microorganism, for example, a virus, a fungus, a protozoa, or a bacterium, more preferably a virus or a protozoa. When the infectious microorganism is a virus, it is preferably a retrovirus, which is more preferably HIV-1 or HIV-2, and most preferably HIV-1. When the infectious microorganism is a protozoa, it is preferably a malarial parasite, which is more preferably a plasmodium species.

**[0068]** The disease-causing replicating biological entity is a cancer cell, which is preferably a rapidly growing tumor cell, for example, a rapidly growing cancer cell found in breast cancer, colon cancer, lung cancer, or the like.

**[0069]** The method of administering a compound can be applied to any suitable biochemical target, preferably a biochemical target whose biochemical vitality can be determined using measurable properties that can be obtained by assay. The biochemical target of the predecessor (and the mutant) is an enzyme and the compound inhibits an enzyme of the predecessor. The enzyme can be any enzyme whose biochemical vitality can be measured including, for example, an enzyme described herein in connection with the fitness assay.

**[0070]** The biochemical target of the disease-causing replicating biological entity is an oligomer and the compound inhibits the oligomerization of the oligomer of the predecessor. The biochemical target of the disease-causing replicating biological entity is a protein and the compound inhibits a conformational change in the protein of the predecessor.

**[0071]** The biochemical vitality can be determined in any suitable manner. For example, vitality can be determined as described herein, e.g., as described in connection with the assay.

**[0072]** When an infectious microorganism is tested in accordance with the assay, the predecessor can be a wild-type species, or the predecessor can itself be a mutant species. The predecessor is a retrovirus, which is more preferably a wild-type HTV-1 or HIV-2 strain, most preferably HIV-1. When the predecessor is a wild-type HIV strain, the mutant replicating biological entity preferably has at least one mutation in the biochemical target thereof. When the predecessor has at least one mutation in the biochemical target thereof, the mutant preferably has at least two mutations in the biochemical target thereof.

**[0073]** Similarly, when the method of administering a therapeutic compound is used in connection with an infectious microorganism, the disease-causing replicating biological entity can be a wild-type species, or the disease-causing entity can itself be a mutant species. The disease-causing replicating biological entity is a retrovirus, which is more preferably a wild-type HIV-1 or HIV-2 strain, most preferably HIV-1. When the disease-causing replicating biological entity is a wild-type HIV strain, the mutant preferably has at least one mutation in the biochemical target thereof. When the disease-causing replicating biological entity has at least one mutation in the biochemical target thereof, the mutant preferably has at least two mutations in the biochemical target thereof.


**[0074]** When the predecessor or the disease-causing replicating biological entity in the assay or in the method of administering a compound, is a wild-type HIV strain, the biochemical target of the mutant preferably has at least one active site mutation. When the predecessor in the assay has at least one mutation, and the mutant replicating biological entity has at least two mutations, the biochemical target of the predecessor or of the mutant preferably has at least one active site mutation. When the disease-causing replicating biological entity in the method has at least one mutation in the biochemical target thereof, and the mutant has at least two mutations in the biochemical target thereof, the biochemical target of the disease-causing entity or of the mutant preferably has at least one active site mutation.

**[0075]** A continuous fluorogenic assay for measuring the anti-HIV protease activity of a protease inhibitor may be provided, which method comprises adding a solution of HIV protease to a substrate stock solution, in which the substrate has the formula Ala-Arg-Val-Tyr-Phe(NO<sub>2</sub>)-Glu-Ala-Nle-NH<sub>2</sub>, to provide a substrate reaction solution. The fluorescence of the substrate reaction solution is then measured at specified time intervals. The solution of HIV protease is then added to a solution of the protease inhibitor and the substrate stock solution, to provide an inhibitor-substrate reaction solution. The fluorescence of the inhibitor-substrate reaction solution is then measured at specified time intervals. The initial velocity of the inhibitor-substrate reaction solution is then calculated by applying the equation:

$$V = V_0 / 2E_t \left( [K_i(1+S/K_m) + I_t E_t]^2 + 4K_i(1+S/K_m)E_t \right)^{1/2} - [K_i(1+S/K_m) + I_t E_t]$$
, wherein V is the initial velocity of the inhibitor reaction solution, V<sub>0</sub> is the initial velocity of the substrate reaction solution, K<sub>m</sub> is the Michaelis-Menten constant, S is the substrate concentration, E<sub>t</sub> is the protease concentration, and I<sub>t</sub> is the inhibitor concentration.


**[0076]** The assay method described herein is highly sensitive and particularly useful for the prediction of the antiviral inhibitory activity of a compound against mutant HIV, more particularly multiple mutant HIV, specifically multidrug-resistant human immunodeficiency viruses. The continuous fluorogenic assay is distinctly advantageous in that it is more sensitive than standard assays in determining the activity of protease inhibitors against multidrug-resistant HIV. The continuous fluorogenic assay is disclosed in more detail in the examples that follow. The inhibitory data obtained in accordance with this continuous fluorogenic assay can be used to determine vitality and fitness for HIV-1 protease in the presence of a protease inhibitor.

**[0077]** The present invention provides the use of a compound of the formula:



or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of said compound, said salt, said prodrug, or said ester thereof, wherein:

A is a group of the formula:



R<sup>1</sup> is H or an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkylalkyl, an aryl, an aralkyl, a heterocycloalkyl, a heterocycloalkylalkyl, a heteroaryl, or a heteroarylalkyl, in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of OR<sup>7</sup>, SR<sup>7</sup>, CN, NO<sub>2</sub>, N<sub>3</sub>, and a halogen, wherein R<sup>7</sup> is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

Y and Z are the same or different and each is selected from the group consisting of CH<sub>2</sub>, O, S, SO, SO<sub>2</sub>, NR<sup>8</sup>, R<sup>8</sup>C(O)N, R<sup>8</sup>C(S)N, R<sup>8</sup>OC(O)N, R<sup>2</sup>OC(S)N, R<sup>8</sup>SC(O)N, R<sup>8</sup>R<sup>9</sup>NC(O)N, and R<sup>8</sup>R<sup>9</sup>NC(S)N, wherein R<sup>8</sup> and R<sup>9</sup> are the same or different and each is selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

n is an integer from 1 to 5;

X is a covalent bond, CHR<sup>10</sup>, CHR<sup>10</sup>CH<sub>2</sub>, CH<sub>2</sub>CHR<sup>10</sup>, O, NR<sup>10</sup>, or S, wherein R<sup>10</sup> is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

Q is C(O), C(S), or SO<sub>2</sub>;

R<sup>2</sup> is H, a C<sub>1</sub>-C<sub>6</sub> alkyl, a C<sub>2</sub>-C<sub>6</sub> alkenyl, or a C<sub>2</sub>-C<sub>6</sub> alkynyl;

m is an integer from 0 to 6;

R<sup>3</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of alkyl, (CH<sub>2</sub>)<sub>p</sub>R<sup>11</sup>, OR<sup>12</sup>, SR<sup>12</sup>, CN, N<sub>3</sub>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, C(O)R<sup>12</sup>, C(S)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, C(O)SR<sup>12</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, C(S)NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>C(S)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>13</sup>, NR<sup>12</sup>C(O)SR<sup>13</sup>, and a halogen, wherein:

p is an integer from 0 to 5;

R<sup>11</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH, OCH<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, SH, and CN; and

R<sup>12</sup> and R<sup>13</sup> are the same or different and each is selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

R<sup>4</sup> is OH, =O (keto) or NH<sub>2</sub>, wherein, when R<sup>4</sup> is OH, it is optionally in the form of a pharmaceutically acceptable ester or prodrug, and when R<sup>4</sup> is NH<sub>2</sub>, it is optionally an amide, a hydroxylamino, a carbamate, a urea, an alkylamino, a dialkylamino, a protic salt thereof, or a tetraalkylammonium salt thereof;

R<sup>5</sup> is H, a C<sub>1</sub>-C<sub>6</sub> alkyl radical, a C<sub>2</sub>-C<sub>6</sub> alkenyl radical, or (CH<sub>2</sub>)<sub>q</sub>R<sup>14</sup>, wherein q is an integer from 0 to 5, and R<sup>14</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH, OCH<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, SH, and CN;

W is C(O), C(S), or SO<sub>2</sub>; and

R<sup>6</sup> is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OR<sup>15</sup>, SR<sup>15</sup>, S(O)R<sup>15</sup>, SO<sub>2</sub>R<sup>15</sup>, SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, SO<sub>2</sub>N(OH)R<sup>15</sup>, CN, CR<sup>15</sup>=NR<sup>16</sup>, CR<sup>15</sup>=N(OR<sup>16</sup>), N<sub>3</sub>, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, N(OH)R<sup>15</sup>, C(O)R<sup>15</sup>, C(S)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup>, C(O)SR<sup>15</sup>, C(O)NR<sup>15</sup>R<sup>16</sup>, C(S)NR<sup>15</sup>R<sup>16</sup>, C(O)N(OH)R<sup>15</sup>, C(S)N(OH)R<sup>15</sup>, NR<sup>15</sup>C(O)R<sup>16</sup>, NR<sup>15</sup>C(S)R<sup>16</sup>, N(OH)C(O)R<sup>15</sup>, N(OH)C(S)R<sup>15</sup>, NR<sup>15</sup>CO<sub>2</sub>R<sup>16</sup>, N(OH)CO<sub>2</sub>R<sup>15</sup>, NR<sup>15</sup>C(O)SR<sup>16</sup>, NR<sup>15</sup>C(O)NR<sup>16</sup>R<sup>17</sup>, NR<sup>15</sup>C(S)NR<sup>16</sup>R<sup>17</sup>, N(OH)C(O)NR<sup>15</sup>R<sup>16</sup>, N(OH)C(S)NR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>C(O)N(OH)R<sup>16</sup>, NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup>, NHSO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>SO<sub>2</sub>NHR<sup>16</sup>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), an alkyl, an alkoxy, an alkylthio, an alkylamino, a cycloalkyl, a cycloalkylalkyl, a heterocycloalkyl, a heterocycloalkylalkyl, an aryl, an aryloxy, an arylamino, an arylthio, an aralkyl, an aryloxyalkyl, an arylaminoalkyl, an aralkoxy, an (aryloxy)alkoxy, an (arylamino)alkoxy, an (arylthio)alkoxy, an aralkylamino, an (aryloxy)alkylamino, an (arylamino)alkylamino, an (arylthio)alkylamino, an aralkylthio, an (aryloxy)alkylthio, an (arylamino)alkylthio, an (arylthio)alkylthio, a heteroaryl, a heteroaryloxy, a heteroarylamino, a heteroarylthio, a heteroarylalkyl, a heteroarylalkoxy, a heteroarylalkylamino, and a heteroarylalkylthio,

wherein R<sup>15</sup>, R<sup>16</sup>, and R<sup>17</sup> are H, an unsubstituted alkyl, or an unsubstituted alkenyl,

wherein, when at least one hydrogen atom of R<sup>6</sup> is substituted with a substituent other than a halogen, OR<sup>15</sup>, SR<sup>15</sup>, CN, N<sub>3</sub>, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, C(O)R<sup>15</sup>, C(S)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup>, C(O)SR<sup>15</sup>, CCO)NR<sup>15</sup>R<sup>16</sup>, C(S)NR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>C(O)R<sup>16</sup>, NR<sup>15</sup>C(S)R<sup>16</sup>, NR<sup>15</sup>CO<sub>2</sub>R<sup>16</sup>, NR<sup>15</sup>C(O)SR<sup>16</sup>, NR<sup>15</sup>C(O)NR<sup>16</sup>R<sup>17</sup>, or NR<sup>15</sup>C(S)NR<sup>16</sup>R<sup>17</sup>, at least one hydrogen atom on said substituent is optionally substituted with a halogen, OR<sup>15</sup>, SR<sup>15</sup>, CN, N<sub>3</sub>, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, C(O)R<sup>15</sup>, C(S)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup>, CCO)SR<sup>15</sup>,

$C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)R^{15}$ ,  $NR^{15}C(S)R^{16}$ ,  $NR^{15}CO_2R^{16}$ ,  $NR^{15}C(O)SR^{16}$ ,  $NR^{15}C(O)NR^{16}R^{17}$ , or  $NR^{15}C(S)NR^{16}R^{17}$ ; in a resistance-inhibiting effective amount in the preparation of a medicament for treating an HIV-infected mammal, in combination with an antiviral agent selected from the group consisting of ritonavir, indinavir, and saquinavir in a pharmaceutically acceptable carrier.

**[0078]** In the practice of the use of preventing the emergence of drug resistance in an HIV-infected mammal, it is preferable that a mutant virus that is capable of evolving from the infection has low fitness, relative to the infecting virus, in the presence of the compound or combination of compounds that are administered.

**[0079]** As utilized herein, the term "alkyl" means a straight-chain or branched alkyl radical containing from about 1 to about 20 carbon atoms chain, preferably from about 1 to about 10 carbon atoms, more preferably from about 1 to about 8 carbon atoms, still more preferably from about 1 to about 6 carbon atoms. Examples of such substituents include methyl, ethyl, propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, pentyl, isoamyl, hexyl, octyl, dodecanyl, and the like.

**[0080]** The term "alkenyl" means a straight-chain or branched-chain alkenyl radical having one or more double bonds and containing from about 2 to about 20 carbon atoms chain, preferably from about 2 to about 10 carbon atoms, more preferably from about 2 to about 8 carbon atoms, still more preferably from about 2 to about 6 carbon atoms. Examples of such substituents include vinyl, allyl, 1,4-butadienyl, isopropenyl, and the like.

**[0081]** The term "alkynyl" means a straight-chain or branched-chain alkynyl radical having one or more triple bonds and containing from about 2 to about 20 carbon atoms chain, preferably from about 2 to about 10 carbon atoms, more preferably from about 2 to about 8 carbon atoms, still more preferably from about 2 to about 6 carbon atoms. Examples of such radicals include ethynyl, propynyl (propargyl), butynyl, and the like.

**[0082]** The term "alkoxy" means an alkyl ether radical, wherein the term "alkyl" is defined as above. Examples of alkoxy radicals include methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, isobutoxy, *sec*-butoxy, *tert*-butoxy, hexanoxy, and the like.

**[0083]** The term "alkylthio" means an alkyl thioether radical, wherein the term "alkyl" is defined as above. Examples of alkylthio radicals include methylthio (SCH<sub>3</sub>), ethylthio (SCH<sub>2</sub>CH<sub>3</sub>), *n*-propylthio, isopropylthio, *n*-butylthio, isobutylthio, *sec*-butylthio, *tert*-butylthio, *n*-hexylthio, and the like.

**[0084]** The term "alkylamino" means an alkyl amine radical, wherein the term "alkyl" is defined as above. Examples of alkylamino radicals include methylamino (NHCH<sub>3</sub>), ethylamino (NHCH<sub>2</sub>CH<sub>3</sub>), *n*-propylamino, isopropylamino, *n*-butylamino, isobutylamino, *sec*-butylamino, *tert*-butylamino, *n*-hexylamino, and the like.

**[0085]** The term "cycloalkyl" means a monocyclic or a polycyclic alkyl radical defined by one or more alkyl carbocyclic rings, which can be the same or different when the cycloalkyl is a polycyclic radical having 3 to about 10 carbon atoms in the carbocyclic skeleton in each ring, preferably about 4 to about 7 carbon atoms, more preferably 5 to 6 carbon atoms. Examples of monocyclic cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclodecyl, and the like. Examples of polycyclic cycloalkyl radicals include decahydronaphthyl, bicyclo[5.4.0]undecyl, adamantyl, and the like.

**[0086]** The term "cycloalkylalkyl" means an alkyl radical as defined herein, in which at least one hydrogen atom on the alkyl radical is replaced by a cycloalkyl radical as defined herein. Examples of cycloalkylalkyl radicals include cyclohexylmethyl, 3-cyclopentylbutyl, and the like.

**[0087]** The term "heterocycloalkyl" means a cycloalkyl radical as defined herein (including polycyclics), wherein at least one carbon which defines the carbocyclic skeleton is substituted with a heteroatom such as, for example, O, N, or S, optionally comprising one or more double bond within the ring, provided the ring is not heteroaryl as defined herein. The heterocycloalkyl preferably has 3 to about 10 atoms (members) in the carbocyclic skeleton of each ring, preferably about 4 to about 7 atoms, more preferably 5 to 6 atoms. Examples of heterocycloalkyl radicals include epoxy, aziridyl, oxetanyl, tetrahydrofuranlyl, dihydrofuranlyl, piperadyl, piperidinyl, piperazyl, piperazinyl, pyranyl, morpholinyl, and the like.

**[0088]** The term "heterocycloalkylalkyl" means an alkyl radical as defined herein, in which at least one hydrogen atom on the alkyl radical is replaced by a heterocycloalkyl radical as defined herein. Examples of heterocycloalkylalkyl radicals include 2-morpholinomethyl, 3-(4-morpholino)-propyl, 4-(2-tetrahydrofuranlyl)-butyl, and the like.

**[0089]** The term "aryl" refers to an aromatic carbocyclic radical, as commonly understood in the art, and includes monocyclic and polycyclic aromatics such as, for example, phenyl and naphthyl radicals, optionally substituted with one or more substituents selected from the group consisting of a halogen, an alkyl, alkoxy, amino, cyano, nitro, and the like.

**[0090]** The term "aryloxy" means aryl as defined herein, wherein a hydrogen atom is replaced by an oxygen.

**Examples of aryloxy radicals include phenoxy, naphthoxy, 4-fluorophenoxy, and the like.**

**[0091]** The term "arylamino" means aryl as defined herein, wherein a hydrogen atom is replaced by an amine. Examples of arylamino radicals include phenylamino, naphthylamino, 3-nitrophenylamino, 4-aminophenylamino, and the like.

**[0092]** The term "arylthio," means aryl as defined herein, wherein a hydrogen atom is replaced by a sulfur atom. Examples of arylthio radicals include phenylthio, naphthylthio, 3-nitrophenylthio, 4-thiophenylthio, and the like.

**[0093]** The term "aralkyl" means alkyl as defined herein, wherein an alkyl hydrogen atom is replaced by an aryl as defined herein. Examples of aralkyl radicals include benzyl, phenethyl, 3-(2-naphthyl)-butyl, and the like.

**[0094]** The term "aryloxyalkyl" means alkyl as defined herein, wherein an alkyl hydrogen atom is replaced by an aryloxy as defined herein. Examples of aryloxyalkyl radicals include phenoxyethyl, 4-(3-aminophenoxy)-1-butyl, and the like.

**[0095]** The term "arylaminoalkyl" means alkyl as defined herein, wherein an alkyl hydrogen atom is replaced by an arylamino as defined herein. Examples of arylaminoalkyl radicals include phenylaminoethyl, 4-(3-methoxyphenylamino)-1-butyl, and the like.

**[0096]** The term "aralkoxy" means alkoxy as defined herein, wherein an alkyl hydrogen atom is replaced by an aryl as defined herein. Examples of aralkoxy radicals include 2-phenylethoxy, 2-phenyl-1-propoxy, and the like.

**[0097]** The term "(aryloxy)alkoxy" means alkoxy as defined herein, wherein an alkyl hydrogen atom is replaced by an aryloxy as defined herein. Examples of (aryloxy) alkoxy radicals include 2-phenoxyethoxy, 4-(3-aminophenoxy)-1-butoxy, and the like.

**[0098]** The term "(arylamino)alkoxy" means alkoxy as defined herein, wherein an alkyl hydrogen atom is replaced by an arylamino as defined herein. Examples of (arylamino)alkoxy radicals include 2-(phenylamino)-ethoxy, 2-(2-naphthylamino)-1-butoxy, and the like.

**[0099]** The term "(arythio)alkoxy" means alkoxy as defined herein, wherein an alkyl hydrogen atom is replaced by an arythio as defined herein. Examples of (arythio)alkoxy radicals include 2-(phenylthio)-ethoxy, and the like.

**[0100]** The term "aralkylamino" means alkylamino as defined herein, wherein an alkyl hydrogen atom is replaced by an aryl as defined herein. Examples of aralkylamino radicals include 2-phenethylamino, 4-phenyl-*n*-butylamino, and the like.

**[0101]** The term "(aryloxy)alkylamino" means alkylamino as defined herein, wherein an alkyl hydrogen atom is replaced by an aryloxy as defined herein. Examples of (aryloxy)alkylamino radicals include 3-phenoxy-*n*-propylamino, 4-phenoxybutylamino, and the like.

**[0102]** The term "(arylamino)alkylamino" means alkylamino as defined herein, wherein an alkyl hydrogen atom is replaced by an arylamino as defined herein. Examples of (arylamino)alkylamino radicals include 3-(naphthylamino)-1-propylamino, 4-(phenylamino)-1-butylamino, and the like.

**[0103]** The term "(arythio)alkylamino" means alkylamino as defined herein, wherein an alkyl hydrogen atom is replaced by an arythio as defined herein. Examples of (arythio)alkylamino radicals include 2-(phenylthio)-ethylamino, and the like.

**[0104]** The term "aralkylthio" means alkylthio as defined herein, wherein an alkyl hydrogen atom is replaced by an aryl as defined herein. Examples of aralkylthio radicals include 3-phenyl-2-propylthio, 2-(2-naphthyl)-ethylthio, and the like.

**[0105]** The term "(aryloxy)alkylthio" means alkylthio as defined wherein, wherein an alkyl hydrogen atom is replaced by an aryloxy as defined herein. Examples of (aryloxy)alkylthio radicals include 3-phenoxypropylthio, 4-(2-fluorophenoxy)-butylthio, and the like.

**[0106]** The term "(arylamino)alkylthio" means alkylthio as defined herein, wherein an alkyl hydrogen atom is replaced by an arylamino as defined herein. Examples of (arylamino) alkylthio radicals include 2-(phenylamino)-ethylthio, 3-(2-naphthylamino)-*n*-propylthio, and the like.

**[0107]** The term "(arythio)alkylthio" means alkylthio as defined herein, wherein an alkyl hydrogen atom is replaced by an arythio as defined herein. Examples of (arythio) alkylthio radicals include 2-(naphthylthio)-ethylthio, 3-(phenylthio)-propylthio, and the like.

**[0108]** The term "heteroaryl" means a radical defined by an aromatic heterocyclic ring as commonly understood in the art, including monocyclic radicals such as, for example, imidazole, thiazole, pyrazole, pyrrole, furane, pyrazoline, thiophene, oxazole, isoxazol, pyridine, pyridone, pyrimidine, pyrazine, and triazine radicals, and also including polycyclics such as, for example, quinoline, isoquinoline, indole, and benzothiazole radicals, which heteroaryl radicals are optionally substituted with one or more substituents selected from the group consisting of a halogen, an alkyl, alkoxy, amino, cyano, nitro, and the like. It will be appreciated that the heterocycloalkyl and heteroaryl substituents can be coupled to the compounds of the present invention via a heteroatom, such as nitrogen (e.g., 1-imidazolyl).

**[0109]** The term "heteroaryloxy" means heteroaryl as defined herein, wherein a hydrogen atom on the heteroaryl ring is replaced by an oxygen. Heteroaryloxy radicals include, for example, 4-pyridyloxy, 5-quinolyloxy, and the like.

**[0110]** The term "heteroarylamino" means heteroaryl as defined herein, wherein a hydrogen atom on the heteroaryl ring is replaced by an nitrogen. Heteroarylamino radicals include, for example, 4-thiazolylamino, 2-pyridylamino, and the like.

**[0111]** The term "heteroarythio" means heteroaryl as defined herein, wherein a hydrogen atom on the heteroaryl ring is replaced by a sulfur. Heteroarythio radicals include, for example, 3-pyridylthio, 3-quinolythio, 4-imidazolylthio, and the like.

**[0112]** The term "heteroaralkyl" means alkyl as defined herein, wherein an alkyl hydrogen atom is replaced by a heteroaryl as defined herein. Examples of heteroaralkyl radicals include 2-pyridylmethyl, 3-(4-thiazolyl)-propyl, and the like.

**[0113]** The term "heteroaralkoxy" means alkoxy as defined herein, wherein an alkyl hydrogen atom is replaced by a heteroaryl as defined herein. Examples of heteroaralkoxy radicals include 2-pyridylmethoxy, 4-(1-imidazolyl)-butoxy, and the like.

**[0114]** The term "heteroaralkylamino" means alkylamino as defined herein, wherein an alkyl hydrogen atom is replaced by a heteroaryl as defined herein. Examples of heteroaralkylamino radicals include 4-pyridylmethylamino, 3-(2-furanyl)-propylamino, and the like.

**[0115]** The term "heteroaralkylthio" means alkylthio as defined herein, wherein an alkyl hydrogen atom is replaced by a heteroaryl as defined herein. Examples of heteroaralkylthio radicals include 3-pyridylmethylthio, 3-(4-thiazolyl)-propylthio, and the like.

**[0116]** According to a preferred embodiment,

when R<sup>1</sup> is an alkyl, it is a C<sub>1</sub>-C<sub>6</sub> alkyl;

when R<sup>1</sup> is an alkenyl it is a C<sub>2</sub>-C<sub>6</sub> alkenyl;

when R<sup>1</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, R<sup>1</sup> is a 4-7 membered ring;

when R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup> is an unsubstituted alkyl, it is a C<sub>1</sub>-C<sub>6</sub> unsubstituted alkyl;

when R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup> is an unsubstituted alkenyl, it is a C<sub>2</sub>-C<sub>6</sub> unsubstituted alkenyl;

R<sup>3</sup> is a 4-7 membered ring;

R<sup>11</sup> is a 4-7 membered ring;

when R<sup>12</sup> or R<sup>13</sup> is an unsubstituted alkyl, it is a C<sub>1</sub>-C<sub>6</sub> unsubstituted alkyl;

when R<sup>12</sup> or R<sup>13</sup> is an unsubstituted alkenyl, it is a C<sub>2</sub>-C<sub>6</sub> unsubstituted alkenyl;

when R<sup>14</sup> is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, R<sup>14</sup> is a 4-7 membered ring;



when R<sup>6</sup> is a cycloalkyl, a heterocycloalkyl, aryl, or a heteroaryl, R<sup>6</sup> is a 4-7 membered ring;

when R<sup>6</sup> is substituted with a substituent that is an alkyl, an alkylthio, or an alkylamino, the substituent comprises from one to six carbon atoms; and



when R<sup>6</sup> is substituted with a substituent that is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the substituent is a 4-7 membered ring;

or a pharmaceutically acceptable salt, a prodrug, or an ester thereof. According to another embodiment, Q is C(O), R<sup>2</sup> is H, and W is SO<sub>2</sub>, or a pharmaceutically acceptable salt, a prodrug, or an ester thereof.

[0117] According to still another embodiment, said compound is of the formula:




[0118] According to an embodiment, said compound is of the formula:




wherein Ar is a phenyl which is optionally substituted with a substituent selected from the group consisting of methyl, amino, hydroxy, methoxy, methylthio, hydroxymethyl, aminomethyl, and methoxymethyl.

[0119] According to still another embodiment, said compound is of the formula:



or



[0120] According to an embodiment, X is oxygen.

[0121] According to another embodiment, R<sup>5</sup> is isobutyl.


[0122] According to still another embodiment, Ar is a phenyl substituted at the para-position.

[0123] According to an embodiment, Ar is a phenyl substituted at the meta-position.


[0124] According to another embodiment, Ar is a phenyl substituted at the ortho-position.

[0125] According to still another embodiment, Ar is selected from the group consisting of para-aminophenyl, para-tolyl, para-methoxyphenyl, meta-methoxyphenyl, and meta-hydroxymethylphenyl.


[0126] According to an embodiment, said compound is of the formula:




wherein A is



R<sup>3</sup> is Ph, R<sup>5</sup> is



and R<sup>6</sup> is



[0127] According to another embodiment, said HIV-infected mammal is infected with a wild-type HIV.

[0128] According to still another embodiment, said HIV-infected mammal is infected by a mutant HIV with least one protease mutation.

[0129] According to an embodiment, said HIV-infected mammal is infected by a mutant HIV having at least one reverse transcriptase mutation.

[0130] According to another embodiment, the medicament is for inhibiting the protease of a mutant retrovirus in a mammal infected with a mutant retrovirus so as to inhibit the proliferation of said mutant retrovirus in said mammal.

[0131] According to still another embodiment, the medicament is for treating a mutant retroviral infection in a mammal infected with a mutant retrovirus.

[0132] According to an embodiment, said mutant retrovirus is a multidrug-resistant mutant retrovirus.

[0133] According to another embodiment, said mutant retrovirus is a multidrug-resistant HIV retrovirus.

[0134] According to still another embodiment, wherein said mutant retrovirus is a multidrug-resistant HIV-1 retrovirus.

[0135] Suitable Ar substituents include phenyl groups that are substituted at the para position, the meta position, and/or the ortho position. Examples of suitable Ar substituents are shown in Table 4, and in Figures 3 and 5A-5D.

[0136] A resistance-inhibiting effective amount is an amount sufficient to produce an in vivo drug concentration or level in which the biochemical vitality of a mutant HIV is lower than the biochemical vitality of the HIV (predecessor) infecting the HIV-infected mammal. For example, a resistance-inhibiting effective amount is an amount sufficient to produce an in vivo drug concentration or level where the value for biochemical fitness is less than one, when determined by the ratio of the biochemical vitality of the mutant to the biochemical vitality of the predecessor. The compound can be administered to a wild-type HIV-infected mammal to prevent the emergence of first line resistance, or it can be administered to a mammal infected with a mutant-HIV to prevent the emergence of drug resistance due to further mutations.

[0137] The compound may be administered in the form of a pharmaceutical composition. The pharmaceutical composition preferably includes a pharmaceutically acceptable carrier and a resistance-inhibiting effective amount of at least one of the aforesaid compound, alone or in combination with another antiretroviral compound such as, for example, a wild-type HIV protease inhibitor, a mutant HIV retroviral protease inhibitor, or a reverse transcriptase inhibitor. Generally, the pharmaceutical composition of the present invention comprises a resistance-inhibiting effective amount of at least one compound of Formula (I), as disclosed herein, and a pharmaceutically acceptable carrier.

[0138] A pharmaceutical composition may be administered that comprises a resistance-inhibiting effective amount of at least one compound of Formula (IA) or Formula (IB), or a pharmaceutically acceptable salt, prodrug, or ester thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition may comprise a resistance-inhibiting effective amount of at least one compound of Formula (IC) or Formula (ID), or a pharmaceutically acceptable salt, prodrug, or ester thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition may comprise a resistance-inhibiting effective amount of at least one compound of Formula (IE), and pharmaceutically acceptable salts, prodrugs, and esters thereof, and a pharmaceutically acceptable carrier.

[0139] Pharmaceutically acceptable carriers are well-known to those of skill in the art. The choice of a carrier will be determined in part by the particular composition, as well as by the particular mode of administration. Accordingly, there are a wide variety of suitable formulations for administration.

[0140] The pharmaceutical composition may be administered in a form suitable for oral use such as, for example, tablets, troches, lozenges, aqueous or oily suspensions or solutions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art form the manufacture of pharmaceutical compositions, and such compositions can contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide a pharmaceutically elegant and/or palatable preparation.

Tablets can contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for manufacture of tablets. Such excipients can be, for example, inert diluents such as, for example, calcium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents such as, for example, maize starch or alginic acid; binding agents such as, for example, starch, gelatine or acacia, and lubricating agents such as, for example, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

**[0141]** Formulations for oral use also can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example arachis oil, peanut oil, liquid paraffin or olive oil.

**[0142]** Aqueous suspensions typically contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a natural-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan mono-oleate. The aqueous suspensions also can contain one or more preservatives, for example, ethyl or n-propyl p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as, for example, sucrose or saccharin.

**[0143]** Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions can be preserved by the addition of an antioxidant such as, for example, ascorbic acid.

**[0144]** Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, also may be present.

**[0145]** The pharmaceutical composition also can be administered in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, for example, olive oil or arachis oils, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters and ethylene oxide, for example polyoxyethylene sorbitan mono-oleate. The emulsions also can contain sweetening and flavoring agents.

**[0146]** The pharmaceutical composition also can be administered in the form of syrups and elixirs, which are typically formulated with sweetening agents such as, for example, glycerol, sorbitol or sucrose. Such formulations also can contain a demulcent, a preservative and flavoring and coloring agents.

**[0147]** Further, the pharmaceutical composition can be administered in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. Suitable suspensions for parenteral administration can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. Formulations suitable for parenteral administration include, for example, aqueous and nonaqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostates, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilisers, and preservatives. The sterile injectable preparation can be a solution or a suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in water or 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed, for example, are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as, for example, oleic acid find use in the preparation of injectables.

**[0148]** Further, the compound can be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefor melt in the rectum to release the drug. Such materials include, for example, cocoa butter and polyethylene glycols. Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, and foams.

**[0149]** Formulations suitable for topical administration may be presented as cream, gel, pastes, or foams, containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.

**[0150]** The composition can be made into an aerosol formulation to be administered via inhalation. Such aerosol formulations can be placed into pressurized acceptable propellants, such as dechlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.

**[0151]** The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

**[0152]** Any suitable dosage level can be employed in the pharmaceutical compositions. The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a prophylactic or therapeutic response in the animal over a reasonable time frame. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition. Suitable doses and dosage regimens for the prevention of drug resistance can be determined by comparisons to antiretroviral chemotherapeutic agents that are known to inhibit the proliferation of a retrovirus in an infected individual. The preferred dosage is the amount that results in the inhibition of the emergence of mutant drug-resistant retroviruses, particularly the emergence of multidrug-resistant retroviral HIV, without significant side effects. In proper doses and with suitable administration of certain compounds, a wide range of antiretroviral chemotherapeutic compositions are possible. A suitable dose includes a dose or dosage which would be insufficient to completely suppress the growth of a wild-type or predecessor virus, but would be sufficient to inhibit or

effectively suppress the growth of a mutant.

**[0153]** The individual daily dosages for combinations with an antiviral agent selected from the group consisting of zidovudine, didanosine and zalcitabine can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly.

**[0154]** A method of preventing the emergence of multidrug-resistant retroviruses in an HIV-infected mammal may be provided which method comprises administering to the mammal a multidrug resistance-inhibiting effective amount of a compound of the present invention, so as to inhibit the emergence of a multidrug-resistant retrovirus in the mammal. The dose administered to an animal, particularly a human in the context of the present invention, should be sufficient to effect a therapeutic response in the animal over a reasonable time frame. The dose will be determined by the strength of the particular composition employed and the condition of the animal, as well as the body weight of the animal to be treated. The size of the dose will also be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound. Other factors which effect the specific dosage include, for example, bioavailability, metabolic profile, and the pharmacodynamics associated with the particular compound to be administered in a particular patient. One skilled in the art will recognize that the specific dosage level for any particular patient will depend upon a variety of factors including, for example, the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, CD4 count, the potency of the active compound with respect to the particular mutant retroviral strain to be inhibited, and the severity of the symptoms presented prior to or during the course of therapy. What constitutes a resistance-inhibiting effective amount can be determined, in part, by use of one or more of the assays described herein, particularly the fitness assay of the present invention.

**[0155]** One skilled in the art will appreciate that suitable methods of administering compounds and pharmaceutical compositions are available, and, although more than one route can be used to administer a particular composition, a particular route can provide a more immediate and/or more effective reaction than another route.

**[0156]** Numerous compounds have been identified that exhibit potent antiretroviral activity, in particular retroviral protease activity, against wild-type HIV. However, among the fifteen currently FDA-approved antiretroviral agents which are all known potent inhibitors of wild-type HIV, five of which are potent inhibitors of wild-type HIV protease, none of these compounds have the ability to prevent the emergence of drug-resistance mutations that are associated with high level cross resistance. Thus, these inhibitors do not have the ability to suppress the sufficiently fit mutant retroviruses that can (and almost certainly will) emerge under the selection pressure of these inhibitors.

**[0157]** Surprisingly, it has been discovered that compound 32 (shown in Figure 3A), which is a potent wild-type HIV inhibitors, possesses remarkably potent and unprecedented broad-spectrum inhibitory activity against a panel of recombinant mutant HIV protease targets. These enzymes represent the key or primary resistance mutations, most of which occur in the active site region. Based on this finding, the compound was tested against a panel of drug resistant mutant patient isolates of HIV and was found to possess broad spectrum antiviral activity against a wide range of clinically isolated, multiply drug-resistant, human immunodeficiency viruses. Other compounds described herein showed similar activity. The mutant viruses were obtained from infected humans who had received several antiviral drugs. Although applicants do not wish to abound by any one particular theory, it is believed that the combination of the bicyclic ligand (vii) with isostere (vi) gives the antiretroviral compounds of the present invention the unique ability to bind to the active site of the mutant proteases of multiply drug-resistant human immunodeficiency viruses generally, which trait has heretofore not been reported with respect to any known chemotherapeutic and/or experimental HIV protease inhibitor. A wild-type preliminary screen was utilized to determine the antiretroviral activity of analogs against wild-type HIV. It is predicted that compounds of Formula (I), which have potent antiretroviral or protease-inhibitory activity against wild-type HIV, also will be potent inhibitors of drug-resistance, even multiple drug-resistance, in wild-type HIV, or even a mutant thereof.

**[0158]** The resistance-inhibiting compounds of the present invention can be synthesized by any suitable method known in the art. The preferred synthesis method is generally illustrated in Figure 4, which is an representation of the synthetic approach to preparing a preferred series of compounds, wherein a compound of Formula (I) is synthesized in several steps starting from azidoepoxide (i), wherein R<sup>1</sup>-R<sup>17</sup>, m, n, p, Q, W, X, y, and z are defined as above. Referring to Figure 4, amine (ii) is nucleophilically added to azidoepoxide (i), providing aminoalcohol (iii). The amine functional group of aminoalcohol (iii) is then reacted with intermediate (iv), wherein L represents a Leaving group (e.g., halogen, N-oxysuccinimide), which can be displaced by the amine of aminoalcohol (iii), to provide azide (v). Reduction of azide (v), or, when R<sup>5</sup> is not hydrogen, reductive amination with aldehyde R<sup>5</sup>CHO, provides intermediate (vi), which is subsequently coupled with activated bicyclic ligand (vii), to provide -compounds of Formula I. Of course, it will be appreciated by a person of ordinary skill in the art that there are combinations of substituents, functional groups, R-groups, and the like, which are reactive under particular reaction conditions, and require the utilization of an appropriate protecting group or groups, which are known in the art, to ensure that the desired synthetic transformation will take place without the occurrence of undesired side reactions. For example, possible substituents at R<sup>5</sup> (e.g., NH<sub>2</sub>) can be competitive nucleophiles requiring the attachment of an appropriate protecting group thereon (e.g., benzyloxycarbonyl, tert-butoxycarbonyl) in order obtain proper selectivity in the ring opening of epoxide (i) with amine (ii).

**[0159]** Figures 1-3B illustrate the synthesis of a preferred series of compounds for use in the method of preventing the emergence of resistance in accordance with the present invention. Figure 1, which is a synthetic scheme for the synthesis of a particular sulfonamide, illustrates the synthesis of a preferred isosteric core, particularly, the sulfonamide isosteric core represented by aminosulfonamide 15. With reference to Figure 1, aminosulfonamide core 15 can be synthesized by initially providing azidoepoxide 11 and subjecting it to nucleophilic addition with amine 12 to give aminoalcohol 13, which is subsequently converted to sulfonamide 14 by reaction with 4-methoxybenzenesulfonyl chloride. The azide group of 14 is then reduced to provide aminosulfonamide 15, which can be used as a core for synthesizing numerous multidrug-resistant retroviral protease inhibitors of the present invention.

**[0160]** Figure 2, which is a reaction scheme detailing the preparation of bicyclic alcohols, illustrates the synthesis of a preferred series of bicyclic ligands, particularly bis-tetrahydrofurans 25 and 26. With reference to Figures 2, dihydrofuran 21 is treated with N-iodosuccinimide in the presence of propargyl alcohol to give iodoether 22, which is cyclized to methylene-substituted bis-tetrahydrofuran 23. Ozonolysis of the exo-methylene residue of 23, followed by reduction, provides bicyclic racemic alcohol 24, which is resolved to give, separately, bicyclic alcohol 25 and its enantiomeric acetate ester 26, which ester group of 26 is subsequently hydrolyzed to afford enantiomer 27.

**[0161]** Figures 3A and 3B, which are reaction schemes describing the preparation of two protease inhibitors, illustrate the preparation of two preferred multidrug-resistant HIV protease inhibitors of the present invention. With reference to Figure 3A, compound 32 was synthesized by coupling succinimidocarbonate 31 with aminosulfonamide 15. Succinimidocarbonate 31 was prepared by reacting optically pure bicyclic alcohol 25 with disuccinimidyl carbonate in the presence of triethylamine. Inhibitor 34, which possesses the enantiomeric bis-tetrahydrofuranyl ligand (relative to inhibitor 32), was prepared in the same fashion, except that the enantiomeric bicyclic alcohol 27 was used instead of alcohol 25, as illustrated in Figure 3B.

**[0162]** The following examples further illustrate the present invention but, of course, should not be construed as in any way limiting its scope.



**Example 1**

**[0163]** This example describes the synthesis of exemplary epoxide 11 (Figure 1), which is used as an intermediate in the synthesis of a particular series of compounds

**[0164]** Anhydrous CuCN (4.86 g, 54 mmol) was added to a solution of butadiene monooxide (38 g, 540 mmol) in anhydrous tetrahydrofuran (1.2 L) and the resulting mixture was stirred at -78 °C. Commercial phenyl magnesium bromide solution (Aldrich) in ether (65 mmol) was added dropwise over a period of 10 min. The resulting reaction mixture was then allowed to warm to 0 °C and it was continued to stir until the reaction mixture was homogeneous. After this period, the reaction mixture was cooled to -78 °C and 0.58 mole of phenylmagnesium bromide solution in ether was added dropwise for 30 min. The reaction mixture was allowed to warm to 23 °C for 1 h. The reaction was quenched by slow addition of saturated aqueous NH<sub>4</sub>Cl (120 mL) followed by NH<sub>4</sub>OH (70 mL), saturated NH<sub>4</sub>Cl (500 mL) and then H<sub>2</sub>O (300 mL). The aqueous layer was thoroughly extracted with ethyl acetate (2 x 300 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was distilled under vacuum (0.12 torr) at 95 °C to give *trans*-4-phenyl-2-butene-1-ol (75.6 g).

**[0165]** To a suspension of powdered 4Å molecular sieves (6.6 g) in anhydrous methylene chloride (750 mL), titanium tetraisopropoxide (Aldrich, 3.2 mL) and then diethyl D-tartrate (2.3 mL) were added. The resulting mixture was cooled to -22 °C and *tert*-butylhydroperoxide solution in isooctane (Aldrich, 430 mmol) was added over a period of 10 min. The mixture was stirred an additional 30 min and then a solution of *trans*-4-phenyl-2-butene-1-ol (32.6 g, 213 mmol), in anhydrous methylene chloride (120 mL), was added dropwise over a period of 40 min at -22 °C. The reaction mixture was then aged in a freezer at -22 °C for 24 h. After this period, water (100 mL) was added to the reaction mixture at -22 °C and the mixture was allowed to warm to 0 °C. After stirring at 0 °C for 45 min, 20% NaOH in brine (20 mL) was added. The resulting mixture was then allowed to warm to 23 °C and was stirred at that temperature for 1 h. After this period, the layers were separated and the aqueous layer was extracted with methylene chloride (2 x 200 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was diluted with toluene (800 mL) and then evaporated under reduced pressure. The residue was chromatographed over silica gel (35% ethyl acetate in hexane as eluent) to provide (2R, 3R)-epoxy-4-phenylbutan-1-ol (21.8 g).

**[0166]** To a solution of titanium isopropoxide (12 mL) in anhydrous benzene (250 mL) was added azidotrimethylsilane (11 mL) and the resulting mixture was refluxed for 6 h. A solution of (2R,3R)-epoxy-4-phenylbutan-1-ol (5.32 g) in anhydrous benzene (25 mL) was added to the above refluxing mixture. The resulting mixture was refluxed for addition 25 min. After this period, the reaction mixture was cooled to 23 °C and the reaction was quenched with aqueous 5% H<sub>2</sub>SO<sub>4</sub> (400 mL). The resulting mixture was stirred for 1 h and the layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 300 mL). The combined organic layers were washed with saturated NaHCO<sub>3</sub> (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford the (2S,3S)-2-hydroxy-3-azido-4-phenylbutan-1-ol (5.1 g) as a white solid (mp 81-82 °C).

**[0167]** To a stirred solution of the azidodiol (5.1 g) in chloroform (100 mL) at 23 °C, 2-acetoxyisobutyryl chloride (Aldrich, 5 mL) was added. The resulting reaction mixture was stirred at 23 °C for 8 h. The reaction was quenched by addition of saturated sodium bicarbonate (100 mL) and the resulting mixture was stirred 30 min. The layers were separated and the aqueous layer was extracted with chloroform (2 x 200 mL). The combined organic layer was extracted with chloroform (2 x 200 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The resulting residue was dissolved in anhydrous THF (50 mL) and solid NaOMe (2.1 g) was added. The mixture was stirred for 4 h at 23 °C and after this period, the reaction was quenched with saturated NH<sub>4</sub>Cl (50 mL). The resulting mixture was extracted with ethyl acetate (2 x 200 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a residue, which was chromatographed over silica gel (10% ethyl acetate in hexanes) to afford the 3(S)-azido-(1,2R)-epoxy-4-phenylbutane 11 (3.3 g) as an oil: <sup>1</sup>H NMR (300 MHz): CDCl<sub>3</sub>; 8.74-7.2 (m, 5H), 3.6 (m, 1H), 3.1 (m, 1H), 2.95 (dd, 1H, J = 4.6, 13.9 Hz), 2.8 (m, 3H).

**Example 2**

**[0168]** This example illustrates the synthesis of azidoalcohol 13 (Figure 1), which can be used as an intermediate in the synthesis of a preferred series of

**[0169]** To a stirred solution of above azidoepoxide 11 (700 mg, 3.7 mmol) in isopropanol (70 mL) was added isobutyl amine (Aldrich, 0.74 mL 7.4 mmol) and the resulting mixture was heated at 80 °C for 12 h. After this period, the reaction mixture was concentrated under reduced pressure and the residue was chromatographed over silica gel to provide azidoalcohol 13 (800 mg) as an oil.

**Example 3**

**[0170]** This example illustrates the synthesis of azidosulfonamide 14, the structure of which is shown in Figure 1.

**[0171]** To a stirred solution of 13 (600 mg, 2.28 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added 4-methoxybenzenesulfonyl -chloride (Aldrich, 530 mg, 2.52 mmol) and saturated aqueous NaHCO<sub>3</sub> (6 mL). The resulting heterogeneous mixture was stirred at 23 °C for 12 h. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> and the layers were separated. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated to dryness. The residue was chromatographed over silica gel (25% ethyl acetate/hexane) to provide 900 mg of azidosulfonamide 14.

**Example 4**

**[0172]** This example illustrate the preparation of aminosulfonamide 15 via reduction of azidosulfonamide 14, as shown in Figure 1.

**[0173]** A solution of 14 (1.53 g) in THF (45 mL), MeOH (10 mL) and acetic acid (0.5 mL), was shaken with 10% palladium on carbon catalyst (200 mg) at 50 psi hydrogen pressure for 2 h. Removal of the catalyst by filtration over celite and concentration under reduced pressure gave a crude residue, which was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL), and was washed successively with saturated aqueous NaHCO<sub>3</sub> and brine. The organic layer was dried over MgSO<sub>4</sub> and concentrated to give the corresponding aminosulfonamide 15 (1.2 g).

**Example 5**

**[0174]** This example demonstrates the synthesis of trans-2-(propargyloxy)-3-iodotetrahydrofuran 22 (Figure 2).

**[0175]** To a stirred, ice-cold suspension of 15 g (66.6 mmol) of N-iodosuccinimide in 150 mL of CH<sub>2</sub>Cl<sub>2</sub> was added a mixture of dihydrofuran 21 (66.6 mmol, 4.67 g, 5.1 mL) and propargyl alcohol (100 mmol, 5.0 g, 5.2 mL) of in 50 mL of CH<sub>2</sub>Cl<sub>2</sub> over 20 min. After warming to 24 °C with stirring over 2 h, 200 mL of water were added and the stirring continued for 1 h. The layers were separated and the aqueous layer was extracted with 2 x 100 mL of CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with brine solution containing small amount of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (70 mg), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Chromatography over silica gel using 30% ethyl acetate in hexane afforded (15.4 g, 92%) the title iodoether 22 as an oil.

#### Example 6

**[0176]** This example illustrates the synthesis of (±)-(3aR, 6aS) and (3aS, 6aR)-3-methylene-4H-hexahydrofuro-[2,3-b]furan 23, as shown in Figure 2.

**[0177]** To a refluxing solution of (20.7 mL, 77 mmol) tributyltin hydride containing AIBN (100 mg) in toluene (200 mL) was added dropwise a solution of 15.4 g (61 mmol) of iodotetrahydrofuran 22 in toluene (50 mL) over a period of 1 h. The resulting mixture was stirred at reflux for an additional 4 h (monitored by TLC). The mixture was then cooled to 23 °C and concentrated under reduced pressure. The residue was partitioned between petroleum ether and acetonitrile (200 mL of each) and the acetonitrile (lower) layer was concentrated. The residue was purified by chromatography on silica gel, using 10% ethyl acetate in hexane as the eluent to provide the title product 23 (5.84 g, 76%) as an oil.

#### Example 7

**[0178]** This example demonstrates the synthesis of (±)-(3SR, 3aRS, 6aS) and (3R, 3aS, 6aR)-3-hydroxy-4H-hexahydrofuro[2,3-b]furan 24, as shown in Figure 2.

**[0179]** A stream of ozone was dispersed into a solution of 15 (5.84 g, 46.4 mmol) at -78 °C in 150 mL of methanol and 150 mL of CH<sub>2</sub>Cl<sub>2</sub> for 30 min. The resulting blue solution was purged with nitrogen until colorless, then quenched with 20 mL of dimethyl sulfide and the resulting mixture was allowed to warm to 23 °C. The mixture was concentrated under reduced pressure to afford the crude ketone. The resulting crude ketone was dissolved in ethanol (50 mL) and the solution was cooled to 0 °C and sodium borohydride (2.1 g, 55.6 mmol) was added. The reaction mixture was stirred for an additional 2 h at 0 °C and then quenched with 10% aqueous citric acid (10 mL). The resulting mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate and brine. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous-Na<sub>2</sub>SO<sub>4</sub> and concentrated carefully under reduced pressure. The resulting residue was chromatographed over silica gel using 30% ethyl acetate in hexane as the eluent to furnish (4.52 g, 75%) the title racemic alcohol 24 as an oil.

#### Example 8

**[0180]** This example illustrates the preparation of immobilized Amano Lipase 30, which was used to resolve racemic aminoalcohol 24 (Figure 2).

**[0181]** Commercially available 4 g of Celite<sup>®</sup> 521 (Aldrich) was loaded on a buchner funnel and washed successively with 50 mL of deionized water and 50 mL of 0.05 N phosphate buffer (pH = 7.0; Fisher Scientific). The washed celite was then added to a suspension of 1 g of Amano lipase 30 in 20 mL of 0.05 N phosphate buffer. The resulting slurry was spread on a glass dish and allowed to dry in the air at 23 °C for 48 h (weight 5.4 g; water content about 2% by Fisher method).

#### Example 9

**[0182]** This example demonstrates the synthesis of (3R,3aS, 6aR) 3-hydroxyhexahydrofuro[2,3-b]furan 25 by immobilized lipase catalyzed acylation, as illustrated in Figure 2.

**[0183]** To a stirred solution of racemic alcohol 24 (2 g, 15.4 mmol) and acetic anhydride (4 g, 42.4 mmol) in 100 mL of DME was added 2.7 g (about 25% by weight of lipase PS30) of immobilized Amano lipase and the resulting suspension was stirred at 23 °C. The reaction was monitored by TLC and <sup>1</sup>H NMR analysis until 50% conversion was reached. The reaction mixture was filtered and the filter cake was washed repeatedly with ethyl acetate. The combined filtrate was carefully concentrated in a rotary evaporator, keeping the bath temperature below 15 °C. The residue was chromatographed over silica gel to provide 843 mg (42%) of 25 (95% ee;  $\alpha_D^{23}$  -11.9°, MeOH); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.85 (m, 2H), 2.3 (m, 1H), 2.9 (m, 1H), 3.65 (dd, J=7.0, 9.1, 1H), 3.85-4.0(m, 3H), 4.45 (dd, J=6.8, 14.6, 1H), 5.7 (d, J=5.1, 1H); also, 1.21 g of 26 after washing with 5% aqueous sodium-carbonate (45%,  $\alpha_D^{23}$  +31.8°, MeOH); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.85-2.1 (m, 2H), 2.1 (s, 3H), 3.1 (m, 1H), 3.75(dd, J=6.6, 9.2, 1H), 3.8-4.1 (m, 3H), 5.2 (dd, J=6.4, 14.5, 1H), 5.7 (d, J=5.2, 1H). Acetate 26 was dissolved in THF (mL) and 1 M aqueous LiOH solution (20 mL) was added to it. The resulting mixture was stirred at 23 °C for 3 h and the reaction was extracted with chloroform (3 x 25 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The residue was chromatographed over silica gel to provide 733 mg of 27 (97% ee;  $\alpha_D^{23}$  -12.5°, MeOH).

#### Example 10

**[0184]** This example demonstrates the synthesis of activated carbonates 31 and 33, as illustrated in Figures 3A and 3B.

**[0185]** To a stirred solution of [3R,3aS, 6aS]-3-hydroxyhexahydrofuro[2,3-b]furan 25 (65 mg, 0.5 mmol) in dry CH<sub>3</sub>CN (5 mL) at 23 °C were added disuccinimidyl carbonate (192 mg, 0.75 mmol) and triethylamine (0.25 mL). The resulting mixture was stirred at 23 °C for 12 h. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and the mixture was concentrated under reduced pressure. The residue was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 25 mL) and the combined organic layers

were washed with brine (10 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent under reduced pressure gave a residue, which was chromatographed over silica gel (50% ethyl acetate/hexane) to furnish (3R, 3aS, 6aR) 3-hydroxyhexahydrofuro[2,3-b]furan-yl-succinimidyl carbonate 31 (70 mg) as a brown oil. Carbonate 33 (65 mg) was prepared from 60 mg of alcohol 27 by following a similar procedure.

#### Example 11

[0186] This example illustrates the preparation of multidrug-resistant HIV inhibitor 32, as illustrated in Figure 3A.

[0187] To a stirred solution of amine 15 (82 mg, 0.2 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added succinimidyl carbonate 31 (55 mg, 0.18 mmol). The resulting solution was stirred at 23°C for 12 h. After this period, the reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (10 mL) and diluted with CH<sub>2</sub>Cl<sub>2</sub> (25 mL). The layers were separated and the organic layer was washed with brine (15 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent under reduced pressure afforded a residue, which was purified by silica gel chromatography (75% ethyl acetate/hexane) to furnish compound 32 (85 mg) as a white solid (m.p. 55-58°C). <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz); δ 7.71 (d, 2H, J=8.8 Hz), 7.29-7.20 (m, 5H), 6.99 (d, 2H, J=7.0 Hz), 5.65 (d, 1H, J=5.19), 5.01 (m, 2H), 3.95-3.82 (m, 7H), 3.69 (m, 2H), 3.0-2.7 (m, 6H), 1.85 (m, 1H), 1.64-1.45 (m, 3H), 0.90 (two d, 6H, J=6.5 Hz, 6.6 Hz).

#### Example 12

[0188] This example illustrates the preparation of multidrug-resistant HIV inhibitor 33, as illustrated in Figure 3B.

[0189] Carbonate 33 (55 mg) was reacted with amine 15 (82 mg, 0.2 mmol) according to the procedure mentioned above to provide compound 34 (81 mg). <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz); δ 7.69 (d, 2H, J=8.8 Hz), 7.28-7.21 (m, 5H), 6.87 (d, 2H, J=5.84 Hz), 5.67 (d, 1H, J=5.46 Hz), 5.0 (m, 2H), 3.86-3.81 (m, 7H), 3.58 (dd, 2H, J=6.6 Hz, 3.6 Hz), 3.17-2.73 (m, 6H), 2.17-1.83 (m, 4H), 0.90 (two d, 6H, J=6.5 Hz, 6.6 Hz).

#### Example 13

[0190] This example describes the protocol for the sensitive continuous fluorogenic assay for HIV protease and its application. Using this assay, the inhibitory activity of compound 32 (Fig. 3A) was tested against the proteases of wild-type HIV-1 (WT) and various mutant enzymes: D30N, V32I, I84V, V32I/I84V, M46F/V82A, G48V/L90M, V82F/I84V, V82T/I84V, V32I/K45I/F53L/A71V/I84V/L89M, V32I/L33F/K45I/F53L/A71V/I84V, and 20R/36I/54V/71V/I82T, which protease enzymes are available from Dr. John W. Erickson, Structural Biochemistry Program, SAIC Frederick, P.O. Box B, Frederick, MD 21702-1201, upon written request. The inhibition constant for wild-type HIV-1, K<sub>imnt</sub>/K<sub>iwT</sub> ratio, and vitality were measured. (See Gulnik et al., Biochemistry, 34, 9282-9287 (1995)). Protease activity was measured using the fluorogenic substrate Lys-Ala-Arg-Val-Tyr-Phe(NO<sub>2</sub>)-Glu-Ala-Nle-NH<sub>2</sub> (Bachem Bioscience, Inc.). (See Peranteau et al., D.H. (1995) Anal. Biochem.).

[0191] Typically, 490 μl of 0.125 M ACES-NaOH buffer, pH 6.2, containing 1.25 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 6.25 mM DTT and 0.1% PEG-8000 was mixed with 5 μl of titrated protease (final concentration 1-5 nM) and incubated 3 min at 37°C. The reaction was initiated by the addition of 5 μl of substrate stock solution in water. Increase in fluorescence intensity at the emission maximum of 306 nm (excitation wavelength was 277 nm) was monitored as a function of time using Aminco Bowman-2 luminescence spectrometer (SLM Instruments, Inc.). The initial rate of hydrolysis was calculated by second degree polynomial fit using SLM AB2 2.0 operating software. Kinetic parameters were determined by nonlinear regression-fitting of initial rate versus substrate concentration data to the Michaelis-Menten equation using program Enzfiter version 1.05.

[0192] For inhibition studies, inhibitors were prepared as stock solutions at different concentrations in dimethylsulfoxide. In a typical experiment 485 μl of 0.125 M ACES-NaOH buffer, pH 6.2, containing 1.25 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 6.25 mM DTT AND 0.1% PEG-8000, was mixed with 5 μl of inhibitor stock solution and 5 μl of titrated protease (final concentration of 1-5 nM) and preincubated 3 min at 37°C. The reaction was initiated by the addition of 5 μl of substrate stock solution in water. For data analysis, the mathematical model for tight-binding inhibitors was used. (See Williams and Morrison (1979), In: Methods of Enzymol. 63, (ed. D.L. Purich), 437-467, Academic Press, NY, London). The data were fitted by nonlinear regression analysis to the equation:  $V = V_0 / 2E_t \left( \left[ \frac{K_1(1+S/K_m) + E_t}{K_1(1+S/K_m) + E_t} \right]^2 + 4K_1(1+S/K_m)E_t \right)^{1/2}$ . [K<sub>1</sub>((1+S/K<sub>m</sub>)+E<sub>t</sub>)] with the program Enzfiter (version 1.05), where V and V<sub>0</sub> are initial velocities with and without inhibitor, respectively, K<sub>m</sub> is a Michaelis-Menten constant, and S, E<sub>t</sub> and I<sub>t</sub> are the concentrations of substrate, active enzyme, and inhibitor, respectively. Biochemical fitness for each mutant was determined by comparing the biochemical vitality of each mutant (vitality<sub>mit</sub>) with the biochemical vitality of the wild-type reference (vitality<sub>wt</sub>), according to the Formula

$$(\text{vitality}_{\text{mut}}) / (\text{vitality}_{\text{wt}}),$$

wherein vitality is (K<sub>1</sub>) (k<sub>cat</sub>/K<sub>M</sub>). The results are shown below in Table 1.

Table 1

Compound 32			
Enzyme	K <sub>1</sub> (pM)	K <sub>I-mut</sub> / K <sub>I-wt</sub>	Biochemical Fitness
WT	14	1	1
D30N	<5	0.33	0.3
V32I	8	0.57	0.5
I84V	40	2.85	1
V32I/I84V	70	5	0.7
M46F/V82A	<5	0.33	0.1
G48V/L90M	<5	0.33	0.1
V82F/I84V	7	0.5	0.1
V82T/I84V	22	1.57	0.1
V32I/K45I/F53L/A71V/I84V/L89M	31	2.2	0.1

Compound 32			
Enzyme	K <sub>1</sub> (pM)	K <sub>1-mut</sub> /K <sub>1-wt</sub>	Biochemical Fitness
V32W/L33F/K4S/I/F 53L/A71V/I84V	46	3.3	0.1
20R/36V/54V/71V/I82T	31	2.2	0.1

[0193] The above results demonstrate that compound 32 is a potent inhibitor of multiple HIV protease mutants that contain the primary or key drug resistance mutations. These data predict that compound 32 will have potent and broad-spectrum multidrug-resistant antiretroviral activity. Moreover, the biochemical fitness of each mutant relative to wild type is equal to or less than one in the presence of compound 32. Based on this fitness profile, it is believed that drug resistant viruses containing the characteristic mutations assayed herein will not emerge from the wild-type in the presence of compound 32.

#### Example 14

[0194] This example illustrates the potent and broad-spectrum multidrug-resistant antiretroviral activity of an exemplary compound of the present invention.

[0195] Compound 32, shown in Figure 3A, was tested side-by-side with four other known HIV-1 protease inhibitors against various wild-type HIV-1 strains (HIV-1<sub>BRS104pre</sub>, HIV-1<sub>LAi</sub>, and HIV-1<sub>BAL</sub>), and mutant multidrug-resistant HIV-1 strains clinically isolated from eight different patients who had received numerous antiviral drugs, either singly or in combination. The patients from which the mutant strains were isolated had a history of anti-HIV therapy with a variety of different drugs such as, for example, zidovudine, zalcitabine, didanosine, ddI, ddC, d4T, 3TC, ABV (abacavir), DLV (delavirdine), and PFA (foscarnet). The patient profiles are shown below in Table 2.

Table 2

patient / Isolate Code	CD4+ (/mm <sup>3</sup> )	HIV-1 RNA level (copies/mL)	Months on Antiviral Therapy	Prior and Present Anti-HIV Therapy
1	361	246,700	64	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, RTV, SQV, AMV, DLV
2	3	553,700	46	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, SQV, AMV
3	108	42,610	39	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, SQV, AMV
4	560	60,000	81	AZT, ddI, ddC, U90, d4T, 3TC, ABV, IDV, SQV, AMV
5	-	-	32	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, SQV, AMV
6	-	-	34	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, SQV, AMV
7	-	-	83	AZT, ddI, ddC, d4T, 3TC, ABV, IDV, SQV, RTV, AMV
8	-	-	69	AZT, ddI, ddC, d4T, 3TC, PFA, ABV, IDV, SQV, AMV

[0196] The four known chemotherapeutic HIV protease inhibitors used for comparative purposes in this example have been utilized in actual human HIV chemotherapy, and are: Ritonavir ("RTV," Abbott Laboratories); Indinavir ("IDV," Merck Research Laboratories); Amprenavir (AMV, See Ghosh et al., Bioorg. Med. Chem. Lett., 8, 687-690 (1998)); and Saquinavir ("SAQ," Roche Research Centre). The IC<sub>50</sub> values (μM) for all five compounds were determined with respect to wild-type and multidrug-resistant HIV-1.

[0197] To determine protease inhibitory activity against multidrug resistant HIV, the IC<sub>50</sub>'s were measured against a panel of clinically isolated mutant HIV isolates. The IC<sub>50</sub>'s were determined by utilizing the PHA-PBMC exposed to HIV-1 (50 TCID<sub>50</sub> dose/1X10<sup>6</sup> PBMC) as target cells and using the inhibition of p24 Gag protein production as an endpoint.

[0198] The IC<sub>50</sub>'s were determined by utilizing the PHA-PBMC assay in which target cells are exposed to HIV-1 (50 TCID<sub>50</sub> dose/1X10<sup>6</sup> PBMC) and inhibition of p24 Gag protein production is used as an endpoint. All drug sensitivities were performed in triplicate. In order to determine whether the HIV isolates were syncytium inducing (SI) or non-syncytium inducing (NSI), an aliquot of viral stock supernatant, containing 100 TCID<sub>50</sub>, was cultured with 1 X 10<sup>5</sup> MT-2 cells in a 12-well plate. Cultures were maintained for four weeks and were examined for syncytium formation twice a week. The results are shown below in Table 3.

Table 3

Phenotype	Patient/ Isolate code (See Table 2)	IC <sub>50</sub> (μM)				
		RTV	IDV	AMV	SAQ	Compound 32
SI	HIV-1 <sub>KRS104pre</sub>	0.055	0.013	0.021	0.01	<0.001
SI	HIV-1 <sub>LAi</sub>	0.0047	0.019	0.019	0.0054	0.0004
NSI	HIV-1 <sub>BAL</sub>	0.018	0.0056	0.014	0.0037	0.0004
	1	>1	>1	0.29	0.29	0.002
	2	>1	0.24	0.24	0.035	<0.001
	3	>1	0.46	0.33	0.036	<0.001

Phenotype	Patient/ Isolate code (See Table 2)	IC <sub>50</sub> (μM)				
		RTV	IDV	AMV	SAQ	Compound 32
NS1	4	>1	0.24	0.4	0.033	0.001
	5	>1	0.8	0.28	0.24	0.002
	6	>1	0.37	0.11	0.19	<0.001
	7	>1	>1	0.42	0.12	0.004
	8	>1	>1	0.22	0.009	0.001



























[0199] The above IC<sub>50</sub>'s clearly demonstrate the broad-spectrum and extraordinarily potent activity of compound 32 against wild-type HIV-1 and the eight different multidrug-resistant clinical isolates tested as was predicted from the biochemical fitness profiles in Example 13. For example, compound 32 exhibits nanomolar and sub-nanomolar potency against all the multidrug-resistant strains tested, whereas Ritonavir, a reasonably potent wild-type inhibitor, is virtually inactive toward the resistant viruses. Moreover, compound 32 is about 9 to about 150 times more potent against the multidrug-resistant viruses than Saquinavir, one of the most potent known compounds against known multidrug-resistant strains of HIV-1. Patients with viral plasma loads greater than 10,000 RNA copies/mm<sup>3</sup> are at risk for developing fatal AIDS complications. There are no effective therapeutic options currently available for these patients infected with these multidrug resistant viruses. Compound 32 and analogs thereof are predicted to be potent in preventing the selection of these viral strains in vivo.

#### Example 15

[0200] This example demonstrates the wild-type antiretroviral activity of the compounds of the present invention.

[0201] It is predicted that the activity of the present inventive compounds against wild-type HIV protease correlates with of antiretroviral activity against multidrug-resistant HIV. Numerous compounds of the present invention were tested against wild-type HIV (See., Ghosh et al., J. Bioorg. Med. Chem. Lett., 8, 6870690 (1998)). Exemplary compounds, which demonstrate potent wild-type HIV protease activity, are shown below in Table 4.

Table 4

						
A	R <sup>3</sup>	R <sup>5</sup>	R <sup>6</sup>	K <sub>i</sub> (nM)	ID <sub>50</sub> (nM)	Comments
	Ph			2.1	4.5	
	Ph			1.1	1.4	Compound 32 (Fig. 3A)
	Ph					Compound 34 (Fig. 3B)
	Ph			1.2	3.5	
	Ph			2.2	4.5	
	Ph					
						
	Ph					

[0202] It is believed that the above compounds in Table 4 will prevent the emergence of resistance in an HIV-infected human.

#### Example 16

[0203] This example demonstrates the oral absorption of compound 32 in an in vivo experimental model.

[0204] Compound 32 was orally administered to a rat at a dose of about 40 mg per kg body mass, using a PEG 300 vehicle as a carrier. The plasma blood levels of compound 32 were measured over a 24 h period after oral administration. The results are shown in Table 5 below.

Table 5

Time After Administration		Plasma Concentration	
Hours	Minutes	(nM)	(ng/mL)
0.28	17	1598	898
1.00	60	878	493
2.07	124	626	352
4.01	240	670	377
6.01	360	594	334
8.05	483	1115	627
12.04	722	246	138
14.08	845	102	57
24.00	1440	82	46

[0205] These results demonstrate that compound 32 maintains high blood levels (e.g., nearly 0.6  $\mu\text{M}$  after 6 hours) long after oral administration. Although applicants do not wish to abound by any one particular theory, it is believed that the non-peptide structure of the compounds of the present invention make them less prone to biological (e.g., enzymatic) degradation, and thereby contribute to their prolonged blood levels after oral administration. From these data, the compounds of the present invention are predicted to have excellent oral bioavailability in humans, and maintain therapeutically significant blood levels over prolonged periods after oral administration.

#### Example 17

[0206] This example demonstrates the influence of human protein binding on the antiviral activity of compound 32. Several potent and orally bioavailable HIV protease inhibitors failed to have in vivo antiviral efficacy. These failures have been ascribed, but not definitively proven, to be due to excessive binding to human plasma proteins, particularly serum albumin and AAG. The protein binding against human alpha acid glycoprotein (AAG, 10  $\mu\text{M}$ ) and against human serum albumin (HAS, 300  $\mu\text{M}$ ) were compared for compound 32 and amprenavir, a structurally related analog that is an FDA approved drug. The results are shown in Table 6.

Table 6

Compound	IC <sub>50</sub> ( $\mu\text{M}$ )		
	(-)	AAG	Alb
32	0.0015 (1X)	0.0022 (1.5X)	0.003 (2X)
amprenavir	0.029 (1X)	0.18 (6X)	0.021 (1X)

[0207] These data demonstrate that the presence of AAG and HAS in physiologically excessive amounts does not adversely affect the antiviral activity of compound 32. From these data, the affinity of compound 32 for human AAG and HSA is predicted to be actually lower than that for amprenavir, a known drug. From these data, the compounds of the present invention are expected to have excellent in vivo efficacy in humans, and maintain therapeutically significant levels over prolonged periods of time.

#### Example 18

[0208] This example describe the inhibitory activity of compounds 35 (Fig. 5A), 36 (Fig. 5B), 37 (Fig. 5C) and 38 (Fig. 5D). In accordance with the technique disclosed in Example 13 above, the inhibitory activity of these compounds was tested against proteases of the wild-type HIV-1. Compound 36, 37 and 38 were also tested against proteases containing the deleterious drug resistance associated mutations V82F/I84V and G48V/V82A. Fitness was determined in accordance with Example 13. The results of these experiments are shown below in Table 7.

Table 7

COMPOUND	ENZYME	K <sub>1</sub> (pM)	K <sub>I-WT</sub> /K <sub>I-MUT</sub>	Fitness
35	WT	81	1	
36	WT	5<		
	V82F/I84V	24.4	>4.9	>0.8
	G48V/V82A	15.3	>3.0	>0.8
37	WT	12	1	
	V82F/I84V	25.7	2.1	0.3
	G48V/V82A	64	5.3	1.4
38	WT	>5		
	V82F/I84V	66.8	>13	>2.1
	G48V/V82A	34	>6.8	>1.8

[0209] These results further demonstrate compounds of the present invention that are potent inhibitors against mutant proteases. Based on the fitness profile, it is believed that drug resistant viruses-containing the characteristic mutations assayed herein will not emerge from the wild-type in the presence of compound 37.

## Example 19

[0210] This example further demonstrates the broad-spectrum and potent activity of exemplary compounds of the present invention against multidrug-resistant clinical isolates.

[0211] The IC<sub>50</sub> values (μM) for all compounds 32, 35, 36, 37, and 38 were determined with respect to wild type clinical isolates HIV-1<sub>LA1</sub> and HIV-1<sub>BAL</sub>. The latter is a monocytotropic strain of HIV.

[0212] The IC<sub>50</sub>'s for isolates HIV-1<sub>LA1</sub> and HIV-1<sub>Ba-L</sub> were determined by exposing the PHA-simulated PBMC to HIV-1 (50 TCID<sub>50</sub> dose/1X10<sup>6</sup> PBMC), in the presence of various concentrations of compounds 32, 35, 36, 37 and 38, and using the inhibition of p24 Gag protein production as an endpoint on day 7 of culture ("p24 assay"). All drug sensitivities were performed in triplicate. The IC<sub>50</sub>'s for isolate HIV-1<sub>LA1</sub> were also determined by exposing MT-2 cells (2x10<sup>3</sup>) to 100 TCID<sub>50</sub>s of HIV-1<sub>LA1</sub> cultured in the presence of various concentrations of compounds 32, 35, 36, 37 and 38. The IC<sub>50</sub>'s were determined using the MTT assay on day 7 of culture. All sensitivities were determined in duplicate. The results are shown below in Table 8.

Table 8

virus	Cell Type /Assay	Comp. 32 IC <sub>50</sub> (μM)	Comp. 35 IC <sub>50</sub> (μM)	Comp. 36 IC <sub>50</sub> (μM)	Coup. 37 IC <sub>50</sub> (μM)	Comp. 38 IC <sub>50</sub> (μM)
HIV-1 <sub>LA1</sub>	MT-2/MTT	0.00022	0.028	0.017	0.0053	0.028
HIV-1 <sub>LA1</sub>	PBMC/p24	0.00022	0.020	0.034	0.0027	0.0080
HIV-1 <sub>LA1</sub>	PBMC/p24	0.00033	0.013	0.038	0.0030	0.0093

[0213] These results demonstrate the potent antiretroviral activity of particular compounds of the present invention.

## Example 20

[0214] This example further illustrates the potent and broad-spectrum multidrug-resistant antiretroviral activity of an exemplary compound of the present invention.

[0215] Compound 32, shown in Figure 3A, was tested against various mutant multidrug-resistant HIV-1 strains clinically isolated from patients. These isolates were all taken from patients who failed therapy on one or more HIV protease inhibitors due to high level clinical resistance. All of these isolates exhibit high level phenotypic resistance in antiviral assays against many of the commonly use HIV protease inhibitor drugs. Compound 32 was tested against these multidrug-resistant clinical isolates side-by-side with known drugs that are commonly used in HIV antiviral therapy, including reverse transcriptase inhibitors such as AZT, 3TC, DDI, DDC, and D4T, and protease inhibitors such as Indinavir (Ind.), Nelfinavir (Nel.), Ritonavir (Rit.), and Saquinavir (Saq.). The IC<sub>50</sub>'s for compound 32 and the comparative drugs against the multidrug-resistant HIV-1 clinical isolates, and against wild-type HIV-1 (WT), are shown in Table 9a.

[0216] The mutant multidrug-resistant HIV-1 strains corresponding to each patient, numbered 9-35, were genetically analyzed in terms of the nucleic acid sequences of the protease (PR) and a portion of the reverse transcriptase (RT) genes from which mutations in these enzymes were determined. The mutations in the protease and reverse transcriptase of the multidrug-resistant viruses isolated from each patient are shown below in Table 9b.

Table 9a

Patient Isolate	IC <sub>50</sub> (μM)									
	AZT	3TC	DDI	DDC	D4T	Ind.	Nel.	Rit.	Saq.	Comp. 32
9	0.01	0.39	0.7	0.15	0.91	1.087	0.98	0.53	>0.3125	0.0003
10	0.02	1.35	1.7	0.37	1.29	>1.25	>1.25	2.03	>0.3125	0.0017
11	0.11	23.61	2.4	0.18	3.10	0.012	0.03	0.01	0.001	0.0004
12	0.07	0.78	0.9	0.20	1.23	>1.25	>1.25	2.47	>0.3125	0.0010
13	0.17	1.04	0.5	<0.1221	0.78	>1.25	0.47	1.64	>0.3125	0.0004
14	0.64		2.4	<0.1221	1.10	0.089	0.01	0.04	0.040	0.0003
15	0.20	>31.25	2.2	0.32	1.10	0.265	0.47	1.14	>0.3125	0.0011
16	0.97	27.98	3.5	0.57	1.81	0.384	0.86	1.34	>0.3125	0.0031
17	>1.25	28.05		0.63	4.28	0.502	0.52	0.87	0.107	0.0022
18	0.55	>31.25	2.2	0.48	2.08	0.369	0.60	3.02	0.039	0.0019
19	>1.25	>31.25	36.6	6.80	35.63	0.784	0.50	2.94	0.055	0.0005
20	1.25	3.21	7.1	0.57	22.54	0.591	0.58	1.90	0.032	
21	>1.25	1.69	1	0.38	3.28	1.250	>1.25	2.18	0.21	0.0023
22	1.02	>31.25	3.7	0.63	4.68	0.173	0.10	0.56	0.003	
23	0.19	>31.25	1.8	0.28	1.00	0.461	0.28	1.82	0.008	0.0004
24										0.0004
25										0.0019
26										0.0019
27	0.03	1.72	2.6	0.41	4.00	>1.25	>1.25	2.97	>0.3125	0.0009
28	>1.25	2.08	2.8	0.36	5.44	1.040	>1.25	2.66	>0.3125	

IC <sub>50</sub> ( $\mu$ M)										
Patient isolate	AZT	3TC	DDI	DDC	D4T	Ind.	Nel.	Rit.	Saq.	Comp. 32
29	>1.25	2.24	3.8	0.34	5.29	0.569	0.67	0.36	0.050	0.0009
30	0.16	>31.25	2.8	0.24	2.52	0.270	0.52	1.03	0.191	0.0019
31		>31.25	2.6	<0.1221	3.11	0.251	0.24	0.85	0.074	0.0010
32	0.32	>31.25	8.4	0.91	2.41	0.223	0.22	0.37	>0.3125	
33	0.51	>31.25	2.0	0.28	2.73	0.133	0.35	0.18	0.059	0.0005
34	>1.25	>31.25	9.1	1.13	7.71	0.595	0.26	3.38	0.063	0.0024
35	0.88	>31.25	17.0	2.46	18.13	0.509	0.48	2.60	0.0616	0.0012
(WT)	0.022	0.264	0.895	0.243	1.059	0.02	0.031	0.019	0.007	0.0007

Table 9b

Isolate	Mutations												
9	PR: V003I	L010I	R041K	G048V	I054S	D062V	L063S	I064L	I064L	A071V	V082A	I093L	
	RT: P004S	V060I	V090I	B122K	I135V	Q174K	Y181C	B194B/K	G196B	R221K	L214F	V145M	R227K
		B297R	L301L/I										
10	PR: V003I	L010I	S037N	R041K	G048V	I054S	I062V	L063S	I064L	I064L	A071V	V082A	I093L
	RT: P004S	V060I	V090I	B122K	I135V	T165A/T	Q174K	Y181C	E194K	G196E	R211K	L214F	H221H/Y
		V245M	R277K										
11	PR: V003I	L010I	I015V	M036I	R037N	R041K	L063T	I093L					
	RT: K020R/K	M041L	K043Q	B044D	V060I	D067N	T069D	E122B/K	D123B	Y181C/Y	M184V	G196B	H208Y
		L210W	R211K										
12	PR: V003I	L010I	I015V	K020R	M036I	S037N	R041K	G048V	I054T/I	L063T	A071V	T074A	V082A/V
		I093L											
	RT: M041L	K043Q	B044D	V060I	D067N	T069D	L074L/I	K103N	D123E	I135T	Y161C	G196B	H208Y
		L201W	R211K										
13	PR: V003I	L010I	I015V	K020R/K	M036I	S037N	R041K	G048V/G	I054T/I	Q058K/Q	Q061R/Q	L063T	A071A/V
		I072T/I	T074A/T	V082A	I093L								
	RT: M041L	K043Q	E044D	V060I	D067N	T069D	L074L/I	K103N	D123E	I135T/I	Y181C	G196E	H208Y
		L210W	R211K										
14	PR: V003I	L010I	K020R	E035D	M036I	S037D	R041K	G048V	L063C	A071V	I072T	V082A/V	I093L
	RT: M041L	T069T/N	L074L/V	E122K	D123E	Y181C	Q207E	L210W	R211K	L214F	T215Y	L228R	K248D
		R277K	E297K										
15	PR: V003I	L010I	E035D	R041K	L063P	A071A/V	I072V/I	G073R/C	V077I	I084V	L090M	I093L	
	RT: D067N	T069D	I142V	E169D	Y181C	M184V	Q207B	R211K	L214F	T215Y	D250E	P272A	Q278E
		L283I	I293V										
16	PR: V003I	L010I	I013V	E035D	S037A	R041K	L063P	A071V	G073S	I084V	L090M		
	RT: K020R	M041L	K043N	D067N	D123N	D177E	I178M/I	M184V	G196E	E203D	L214F	T215Y	K219Q
		R277K	G333E										
17	PR: V003I	L010I	I013V	E035D	S037A	R041K	L063P	A071V	G073G/S	I084V	L090M		
	RT: K020R	M041L	K043N	D067N	D123N	D177B	I178M/I	M184V	G196E	E203D	L214F	T215Y	R277K
		G333E	A360T										
18	PR: V003I	L010V	S037N	K043T	I054V	L063P	A071V	V082A	L090M				
	RT: K020R	V035M	K064H	D067G	T069N	K070R	K102R/K	V1118I	E122K	I135T	E162A	M184V	T215S
		D128E	E219Q										
19	PR: V003I	L010I	L019I	S037Q	M046L	I054V	R057K	L063P	A071V	V082A	L090M		
	RT: K020R	T058N	A062V	S068G	T069T/I	V075I	F077L	A098S	K103N	F116Y	I135T	I142M	Q151M
		Y181C	M184V										
20	PR: V003I	L010I	T012P	K014R	I015V/I	G016E	S037N	M016I	I054V	K055R	I062V	L063N	A071T
		V077I	V082A	I085V	L090M								
	RT: K020R	V035I	T039A	M041L	K043E	E044A	D067N	V075A	K103N	V118I	I135M	Y181C	H208Y
		L210W	R211K										
21	PR: V003I	L010I	I015V	K020R	E035D	M036I	S037K	R041N	K043T/K	M041I	L063P	H069K	A071V
		T074S	V082F	N088E	L084M	L090M	I093L						
	RT: K020R	V035T	T039R	M041L	K043E	E044D	V060I	I063M/I	D067N	T069D	A098G	V118I	D121H
		I135T/I	I142V										
22	PR: V003I	L010I	E034E/Q	S037M	M046I	I054V	I062V	L063S	V082A	L089L/M			
	RT: K020R/K	T039A/T	M011L	K043E	E044D	D067N	V118I	M184V	E203E/K	Q207E	H208Y	L210W	R211K



Isolate	Mutations													
		L214F	T215Y											
23	PR	V003I	L010I	I015V	M20I	L024I	M036I	S037N	I054V	R057K	L063P	A071V	V082A	
	RT	K011R	D067N	K070R	I135T	Y181V/D	M184V	D218E/D	K219Q	P272A	E277K	R284R/K	I293V	E297V
		M357T/M	G359G/S											
24	PR	V003I	I015V	D030N	E035D	S037D	L063P	V077I	N088D					
	RT	K064R	E122K	D123E	D177B		G196R	R211G	L214F	V215T/M	E297A	I326V	I329L	T338S
		N348I	R358K											
25	PR	V003I	K020I	T026T/I	S037N	M046I	L063P	A071V	G073S	V077I	I084V	L090N	I093L	
	RT	V035M	D067N	T069D	K070R	E122P	D177E	M184V	I202V	Q207E	R211K	L211F	T215F	K219Q
		E224K	R277K											
26	PR	V003I	L010I	S037N	R041K	G048V	I054S	I062V	L063S	I064L	A071V	V082A	I093L	
	RT	P004S	V060I	V090I	E122K	I135Y	T135A/T	Q174K	Y81C	E194K	G196E	R211K	L214F	H221H/Y
		V245M	R277K											
27	PR	V003I	L010I	I015V	K020R	M036I	S037N	R041K	G048V	I054T/I	L063T	A071A/V	T074A	V082A
		I093L												
	RT	M041L	K043Q	E044D	V060I	D067N	T069D	L074L/I	K103N	F216F/L	D123E	I135T	Y181C	G196E
		H308Y	L210W											
28	PR	V003I	L010I	I015V	M036I	S037D	G048V	I054V	D060E	Q061E	I062V	I064V	A071V	V082A
		L090M	I093L											
	RT	P004S	M041L	D067N	T069D	R070R	V090I	K103N	I135T	S162A	V179I	Y181C	G196E	Q207E
		L214F	T215F											
29	PR	V003I	L010I	K020I	S037N	M046M/I	L063P	I072I/K	G073C	V077I	L090M			
	RT	V035I	T039A/E	M041L	B044D	L074L/V	R083K	K102Q	S162C	I17AL	E203K	H206Y	L210W	R211K
		L114F	T215Y											
30	PR	V003I	L010I	B035D	R041K	L063P	A071A/V	I072V/I	G073G/S	V077I	I084V/I	L090M	I093L	
	RT	D067N	T069D	I142V	E169D	Y181C	M184V	Q207E	R211K	L214F	T215Y	D250E	P272A	Q278E
		L283I	I293V											
31	PR	V003I	L010L/I	E035D	M036M/I	S037N	M046X	I054V	L063P	I066F	A071V	V082A/T	I094V/I	
	RT	K031R/K	K064R	D067N	K070R	K103N/K	E122K	Y181F/C	M184V	R211K	L214F	D218E	K219Q	E248D
		T286A	I293V											
32	PR	V003I	L010I	S037N	G048V	I054V	I062V/I	L063P	A071A/T	V077I	V082A	I093L		
	RT	K020R	M041L	D123N	I178L	M184V	T200A/T	E203D	Q207E	L210L/W	L214F	T215Y	R277K	T286A
		Q334L/Q	T338S/T											
33	PR	V003I	L010I	E035D	M036I	S037D	D060E	L063P	I064V	I084V	L090M			
	RT	M041L/M	D067N	T063T/N	K070R	D177D/E	M184V	I202V	Q207E	L210W	R211K	L214F	T215Y	K219Q
		V245T	P272A											
34	PR	V003I	L010V	S037N	K043T	I054V	L063P	A071V	V082A	L090M				
	RT	K020R	V035M	K064H	D067G	T069N	K070R	K102R/K	V1181I	E122K	I135T	S162A	M184V	T215S
		D218E	K219Q											
35	PR	V003I	L010I	L019I	S037Q	M046L	I054V	R057K	L063P	A071V	V082A	L090M		
	RT	K020R	T058N	A062V	S068G	T069T/I	V075I	F077L	A098S	K103N	F116Y	I135T	I142M	Q151M
		Y181C	M184V											

[0217] The results of this experiment further show the effectiveness of an exemplary compound of the present invention against a wide range of viral mutants compared to other well-known inhibitors. These mutant viruses represent a panel of the most broadly cross resistant clinical isolates known to date based on their resistance to therapeutically used HIV protease inhibitors. Compound 32 was consistently potent against all of the clinically isolated mutant viruses tested, and was significantly more potent against these multidrug resistant viruses than the comparative drugs which are currently used in human HIV-1 therapy. Compound 32 was ten to one-thousand times more potent against these viruses than even saquinavir, one of the most potent known compounds against multidrug-resistant HIV-1. Based on the high potency, it is believed that these mutants will not only be inhibited, but also that these mutants would not be able to emerge if the compound is administered to a patient infected with a predecessor virus.

[0218] While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications as defined by the following claims.

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

#### Patent documents cited in the description


- [US5725718A \[0012\]](#)
- [US5592060A \[0012\]](#)
- [US5703076A \[0012\]](#)
- [US5475027A \[0012\]](#)

#### Non-patent literature cited in the description

- [KAGEYAMA et al.](#)Antimicrob. Agents Chemother., 1992, vol. 36, 926-933 [\[0008\]](#)
- [MOORE et al.](#)Perspect. Drug Dis. Design, 1993, vol. 1, 85- [\[0009\]](#)
- [TOMASSELLI et al.](#)Int. J. Chem. Biotechnology, 1991, vol. 6, [\[0009\]](#)
- [HUFF](#)J. Med. Chem., 1991, vol. 34, 2305- [\[0009\]](#)
- [NORBECK et al.](#)Ann. Reports Med. Chem., 1991, vol. 26, 141- [\[0009\]](#)
- [MEEK, J.](#)Enzyme Inhibition, 1992, vol. 6, 65- [\[0009\]](#)
- [PLATTNER et al.](#)Drug Discovery Technologies Elish Hbrwood 19900000 [\[0009\]](#)
- [ERICKSON et al.](#)Science, 1990, vol. 249, 527-533 [\[0010\]](#)
- [KRAMER et al.](#)Science, 1986, vol. 231, 1580-1584 [\[0010\]](#)
- [MCQUADE et al.](#)Science, 1990, vol. 247, 454-456 [\[0010\]](#)
- [MEEK et al.](#)Nature (London), 1990, vol. 343, 90-92 [\[0010\]](#) [\[0010\]](#)
- [ROBERTS et al.](#)Science, 1990, vol. 248, 358-361 [\[0010\]](#) [\[0010\]](#)
- [VACCA et al.](#)J. Med. Chem., 1991, vol. 34, 1225-1228 [\[0010\]](#)
- [GHOSH et al.](#)Bioorg. Med. Chem. Lett., 1998, vol. 8, 687-690 [\[0010\]](#) [\[0012\]](#) [\[0196\]](#)
- [GHOAH et al.](#)J. Med. Chem., 1993, vol. 36, 292-295 [\[0010\]](#)
- [RICH et al.](#)J. Med. Chem., 1990, vol. 33, 1285-1288 [\[0010\]](#)
- [OTTO et al.](#)PNAS USA, 1993, vol. 90, 7543- [\[0013\]](#)
- [HO et al.](#)J. Virology, 1994, vol. 68, 2016-2020 [\[0013\]](#)
- [KAPLAN et al.](#)PNAS USA, 1994, vol. 91, 5597-5601 [\[0013\]](#)
- [MAJER et al.](#)13th American Peptide Symposium, Edmonton, Canada, 1993, [\[0013\]](#)
- [LYLE et al.](#)J. Med. Chem., 1991, vol. 34, 1230- [\[0013\]](#)
- [BONE et al.](#)J. Am. Chem. Soc., 1991, vol. 113, 9382- [\[0013\]](#)
- [GULNIK et al.](#)J. Mol. Biol., 1992, vol. 227, 265-270 [\[0047\]](#)
- [DR. JOHN W. ERICKSON](#)Structural Biochemistry Program, SAIC Frederick, P.O. Box B, Frederick, MD 21702-1201, [\[0190\]](#)
- [GULNIK et al.](#)Biochemistry, 1995, vol. 34, 9282-9287 [\[0190\]](#)
- [PERANTEAU et al.](#)Anal. Biochem., 1995, [\[0190\]](#)
- [GHOSH et al.](#)J. Bioorg. Med. Chem. Lett., 1998, vol. 8, 6870690- [\[0201\]](#)


## PATENTKRAV

1. Anvendelse af en forbindelse med formlen:



- 5 eller et farmaceutisk acceptabelt salt, et prodrug eller en ester deraf eller et farmaceutisk acceptabelt præparat af denne forbindelse, dette salt, dette prodrug eller denne ester deraf, hvor:

A er en gruppe med formlen:



- 10  $R^1$  er H eller en alkyl, en alkenyl, en alkynyl, en cycloalkyl, en cycloalkylalkyl, en aryl, en aralkyl, en heterocycloalkyl, en heterocycloalkylalkyl, en heteroaryl eller en heteroaralkyl, i hvilken mindst ét hydrogenatom eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af  $OR^7$ ,  $SR^7$ , CN,  $NO_2$ ,  $N_3$  og et halogen, hvor  $R^7$  er H, en usubstitueret alkyl, en usubstitueret alkenyl eller en usubstitueret alkynyl;
- 15 Y og Z er ens eller forskellige, og hver er valgt fra gruppen bestående af  $CH_2$ , O, S, SO,  $SO_2$ ,  $NR^8$ ,  $R^8C(O)N$ ,  $R^8C(S)N$ ,  $R^8OC(O)N$ ,  $R^8OC(S)N$ ,  $R^8SC(O)N$ ,  $R^8R^9NC(O)N$  og  $R^8R^9NC(S)N$ , hvor  $R^8$  og  $R^9$  er ens eller forskellige, og hver er valgt fra gruppen bestående af H, en usubstitueret alkyl, en usubstitueret alkenyl og en usubstitueret alkynyl;
- 20 n er et helt tal fra 1 til 5;

X er en kovalent binding,  $CHR^{10}$ ,  $CHR^{10}CH_2$ ,  $CH_2CHR^{10}$ , O,  $NR^{10}$  eller S, hvor  $R^{10}$  er H, en usubstitueret alkyl, en usubstitueret alkenyl eller en usubstitueret alkynyl;

Q er C(O), C(S) eller SO<sub>2</sub>;

R<sup>2</sup> er H, en C<sub>1</sub>-C<sub>6</sub> alkyl, en C<sub>2</sub>-C<sub>6</sub> alkenyl eller en C<sub>2</sub>-C<sub>6</sub> alkynyl;

m er et helt tal fra 0 til 6;

5 R<sup>3</sup> er en cycloalkyl, en heterocycloalkyl, en aryl eller en heteroaryl, i hvilken mindst ét hydrogenatom eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af alkyl, (CH<sub>2</sub>)<sub>p</sub>R<sup>11</sup>, OR<sup>12</sup>, SR<sup>12</sup>, CN, N<sub>3</sub>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, C(O)R<sup>12</sup>, C(S)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, CO)SR<sup>12</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, C(S)NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>C(S)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>13</sup>, NR<sup>12</sup>C(O)SR<sup>13</sup> og et halogen, hvor:

p er et helt tal fra 0 til 5;

10 R<sup>11</sup> er en cycloalkyl, en heterocycloalkyl, en aryl eller en heteroaryl, i hvilken mindst ét hydrogenatom eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af et halogen, OH, OCH<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, SH og CN; og

R<sup>12</sup> og R<sup>13</sup> er ens eller forskellige, og hver er valgt fra gruppen bestående af H, en usubstitueret alkyl, en usubstitueret alkenyl og en usubstitueret alkynyl;

15 R<sup>4</sup> er OH, =O (keto) eller NH<sub>2</sub>, hvor, når R<sup>4</sup> er OH, den eventuelt er i form af en farmaceutisk acceptabel ester eller prodrug, og når R<sup>4</sup> er NH<sub>2</sub>, er den eventuelt et amid, en hydroxylamino, et carbamat, et urinstof, en alkylamino, en dialkylamino, et prot salt deraf eller et tetraalkylammoniumsalt deraf;

20 R<sup>5</sup> er H, et C<sub>1</sub>-C<sub>6</sub> alkylradikal, et C<sub>2</sub>-C<sub>6</sub> alkenylradikal eller (CH<sub>2</sub>)<sub>q</sub>R<sup>14</sup>, hvor q er et helt tal fra 0 til 5, og R<sup>14</sup> er et cycloalkyl-, et heterocycloalkyl-, et aryl- eller et heteroarylradikal, i hvilket mindst ét hydrogenatom eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af et halogen, OH, OCH<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, SH og CN;

W er C(O), C(S) eller SO<sub>2</sub>; og

25 R<sup>6</sup> er et cycloalkyl-, heterocycloalkyl-, aryl- eller heteroarylradikal, i hvilket mindst ét hydrogenatom eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af et halogen, OR<sup>15</sup>, SR<sup>15</sup>, S(O)R<sup>15</sup>, SO<sub>2</sub>R<sup>15</sup>, SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, SO<sub>2</sub>N(OH)R<sup>15</sup>, CN, CR<sup>15</sup>=NR<sup>16</sup>, CR<sup>15</sup>=N(OR<sup>16</sup>), N<sub>3</sub>, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, N(OH)R<sup>15</sup>, C(O)R<sup>15</sup>, C(S)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup>, C(O)SR<sup>15</sup>, C(O)NR<sup>15</sup>R<sup>16</sup>, C(S)NR<sup>15</sup>R<sup>16</sup>, C(O)N(OH)R<sup>15</sup>, C(S)N(OH)R<sup>15</sup>,

$\text{NR}^{15}\text{C}(\text{O})\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{S})\text{R}^{16}$ ,  $\text{N}(\text{OH})\text{C}(\text{O})\text{R}^{15}$ ,  $\text{N}(\text{OH})\text{C}(\text{S})\text{R}^{15}$ ,  $\text{NR}^{15}\text{CO}_2\text{R}^{16}$ ,  
 $\text{N}(\text{OH})\text{CO}_2\text{R}^{15}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{SR}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{NR}^{16}\text{R}^{17}$ ,  $\text{NR}^{15}\text{C}(\text{S})\text{NR}^{16}\text{R}^{17}$ ,  
 $\text{N}(\text{OH})\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $\text{N}(\text{OH})\text{C}(\text{S})\text{NR}^{15}\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{N}(\text{OH})\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{S})\text{N}(\text{OH})\text{R}^{16}$ ,  
 $\text{NR}^{15}\text{SO}_2\text{R}^{16}$ ,  $\text{NHSO}_2\text{NR}^{15}\text{R}^{16}$ ,  $\text{NR}^{15}\text{SO}_2\text{NHR}^{16}$ ,  $\text{P}(\text{O})(\text{OR}^{15})(\text{OR}^{16})$ , en alkyl, en alkoxy,  
5 en alkylthio, en alkylamino, en cycloalkyl, en cycloalkylalkyl, en heterocycloalkyl, en  
heterocycloalkylalkyl, en aryl, en aryloxy, en arylamino, en arylthio, en aralkyl, en aryl-  
oxyalkyl, en arylaminoalkyl, en aralkoxy, en (aryloxy)alkoxy, en (arylamino)alkoxy, en  
(arylthio)alkoxy, en aralkylamino, en (aryloxy)alkylamino, en (arylamino)alkylamino, en  
(arylthio)alkylamino, en aralkylthio, en (aryloxy)alkylthio, en (arylamino)alkylthio, en  
10 (arylthio)alkylthio, en heteroaryl, en heteroaryloxy, en heteroarylamino, en heteroaryl-  
thio, en heteroaralkyl, en heteroaralkoxy, en heteroaralkylamino og en heteroaralkyl-  
thio,

hvor  $\text{R}^{15}$ ,  $\text{R}^{16}$  og  $\text{R}^{17}$  er H, en usubstitueret alkyl eller en usubstitueret alkenyl,

15 hvor, når mindst ét hydrogenatom af  $\text{R}^6$  er substitueret med en anden substituent end  
et halogen,  $\text{OR}^{15}$ ,  $\text{SR}^{15}$ ,  $\text{CN}$ ,  $\text{N}_3$ ,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{C}(\text{O})\text{R}^{15}$ ,  $\text{C}(\text{S})\text{R}^{15}$ ,  $\text{CO}_2\text{R}^{15}$ ,  $\text{C}(\text{O})\text{SR}^{15}$ ,  
 $\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $\text{C}(\text{S})\text{NR}^{15}\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{S})\text{R}^{16}$ ,  $\text{NR}^{15}\text{CO}_2\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{SR}^{16}$ ,  
 $\text{NR}^{15}\text{C}(\text{O})\text{NR}^{16}\text{R}^{17}$  eller  $\text{NR}^{15}\text{C}(\text{S})\text{NR}^{16}\text{R}^{17}$ , mindst ét hydrogenatom på denne substitu-  
ent eventuelt er substitueret med et halogen,  $\text{OR}^{15}$ ,  $\text{SR}^{15}$ ,  $\text{CN}$ ,  $\text{N}_3$ ,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  
 $\text{C}(\text{O})\text{R}^{15}$ ,  $\text{C}(\text{S})\text{R}^{15}$ ,  $\text{CO}_2\text{R}^{15}$ ,  $\text{C}(\text{O})\text{SR}^{15}$ ,  $\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $\text{C}(\text{S})\text{NR}^{15}\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{R}^{15}$ ,  
20  $\text{NR}^{15}\text{C}(\text{S})\text{R}^{16}$ ,  $\text{NR}^{15}\text{CO}_2\text{R}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{SR}^{16}$ ,  $\text{NR}^{15}\text{C}(\text{O})\text{NR}^{16}\text{R}^{17}$  eller  $\text{NR}^{15}\text{C}(\text{S})\text{NR}^{16}\text{R}^{17}$ ; i  
en resistens-inhiberende effektiv mængde, til fremstilling af et lægemiddel til behand-  
ling af et HIV-inficeret pattedyr i kombination med et antiviralt middel, som er valgt fra  
gruppen bestående af ritonavir, indinavir og saquinavir, i en farmaceutisk acceptabel  
bærer.

25

2. Anvendelse ifølge krav 1, hvor:

når  $\text{R}^1$  er en alkyl, er den en  $\text{C}_1$ - $\text{C}_6$  alkyl;

når  $\text{R}^1$  er en alkenyl, er den en  $\text{C}_2$ - $\text{C}_6$  alkenyl;

30 når  $\text{R}^1$  er en cycloalkyl, en heterocycloalkyl, en aryl eller en heteroaryl, er  $\text{R}^1$  en 4-7-  
leddet ring;

når  $R^7$ ,  $R^8$  eller  $R^9$  er en usubstitueret alkyl, er den en  $C_1$ - $C_6$  usubstitueret alkyl;

når  $R^7$ ,  $R^8$  eller  $R^9$  er en usubstitueret alkenyl, er den en  $C_2$ - $C_6$  usubstitueret alkenyl;

$R^3$  er en 4-7-leddet ring;

$R^{11}$  er en 4-7-leddet ring;

5 når  $R^{12}$  eller  $R^{13}$  er en usubstitueret alkyl, er den en  $C_1$ - $C_6$  usubstitueret alkyl;

når  $R^{12}$  eller  $R^{13}$  er en usubstitueret alkenyl, er den en  $C_2$ - $C_6$  usubstitueret alkenyl;

når  $R^{14}$  er en cycloalkyl, en heterocycloalkyl, en aryl eller en heteroaryl, er  $R^{14}$  en 4-7-leddet ring;

10 når  $R^6$  er en cycloalkyl, en heterocycloalkyl, aryl eller en heteroaryl, er  $R^6$  en 4-7-leddet ring;


når  $R^6$  er substitueret med en substituent, som er en alkyl, en alkylthio eller en alkyl-amino, omfatter substituenten fra ét til seks carbonatomer; og

når  $R^6$  er substitueret med en substituent, som er en cycloalkyl, en heterocycloalkyl, en aryl eller en heteroaryl, er substituenten en 4-7-leddet ring;


15 eller et farmaceutisk acceptabelt salt, et prodrug eller en ester deraf.

3. Anvendelse ifølge krav 1 eller 2, hvor Q er C(O),  $R^2$  er H, og W er  $SO_2$ , eller et farmaceutisk acceptabelt salt, et prodrug eller en ester deraf.

20 4. Anvendelse ifølge krav 1, hvor forbindelsen har formelen:




(IA) or




(IB).

5. Anvendelse ifølge krav 4, hvor forbindelsen har formelen:



(IC) or




(ID),

hvor Ar er en phenyl, som eventuelt er substitueret med en substituent, som er valgt fra gruppen bestående af methyl, amino, hydroxy, methoxy, methylthio, hydroxymethyl, aminomethyl og methoxymethyl.


5

6. Anvendelse ifølge krav 5, hvor forbindelsen har formlen:



(IE)

or



(IF).

10

7. Anvendelse ifølge krav 5 eller 6, hvor X er oxygen.

8. Anvendelse ifølge krav 5 eller 6, hvor R<sup>5</sup> er isobutyl.

15

9. Anvendelse ifølge krav 5 eller 6, hvor Ar er en phenyl, som er substitueret i para-stillingen.


10. Anvendelse ifølge krav 5 eller 6, hvor Ar er en phenyl, som er substitueret i meta-stillingen.




11. Anvendelse ifølge krav 5 eller 6, hvor Ar er en phenyl, som er substitueret i ortho-stillingen.

5 12. Anvendelse ifølge krav 5 eller 6, hvor Ar er valgt fra gruppen bestående af para-aminophenyl, para-tolyl, para-methoxyphenyl, meta-methoxyphenyl og meta-hydroxymethylphenyl.


13. Anvendelse ifølge krav 1, hvor forbindelsen har formelen:




hvor A er



R<sup>3</sup> er Ph, R<sup>5</sup> er



15 og R<sup>6</sup> er



14. Anvendelse ifølge et hvilket som helst af kravene 1, 2, 4-6 eller 13, hvor det HIV-inficerede pattedyr er inficeret med et vildtype-HIV.

20

15. Anvendelse ifølge et hvilket som helst af kravene 1, 2, 4-6 eller 13, hvor det HIV-inficerede pattedyr er inficeret med en HIV-mutant med mindst én proteasemutation.

16. Anvendelse ifølge et hvilket som helst af kravene 1, 2, 4-6 eller 13, hvor det HIV-inficerede pattedyr er inficeret med en HIV-mutant, som har mindst én revers transkriptasemutation.

5

17. Anvendelse ifølge et hvilket som helst af kravene 1, 2, 4-6 eller 13, hvor lægemidlet er til inhibering af proteasen af en retrovirusmutant i et pattedyr, som er inficeret med en retrovirusmutant, med henblik på at inhibere proliferationen af retrovirusmutanten i pattedyret.

10

18. Anvendelse ifølge et hvilket som helst af kravene 1, 2, 4-6 eller 13, hvor lægemidlet er til behandling af en infektion med en retrovirusmutant i et pattedyr, som er inficeret med en retrovirusmutant.

15

19. Anvendelse ifølge krav 17 eller 18, hvor retrovirusmutanten er et multidrug-resistent retrovirusmutant.

20. Anvendelse ifølge krav 17 eller 18, hvor retrovirusmutanten er et multidrug-resistent HIV-retrovirus.

20

21. Anvendelse ifølge krav 17 eller 18, hvor retrovirusmutanten er et multidrug-resistent HIV-1-retrovirus.

## DRAWINGS




Fig. 1




Fig. 2




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D